[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 86 of about 86
1. Zheng X, Zugates CT, Lu Z, Shi L, Bai JM, Lee T: Baboon/dSmad2 TGF-beta signaling is required during late larval stage for development of adult-specific neurons. EMBO J; 2006 Feb 8;25(3):615-27
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baboon/dSmad2 TGF-beta signaling is required during late larval stage for development of adult-specific neurons.
  • The intermingling of larval functional neurons with adult-specific neurons during metamorphosis contributes to the development of the adult Drosophila brain.
  • We found that Baboon(Babo)/dSmad2-mediated TGF-beta signaling, known to be essential for remodeling of larval functional neurons, is also indispensable for proper morphogenesis of these adult-specific neurons.
  • We observe similar phenomena in other adult-specific neurons.
  • We further demonstrate that Babo/dSmad2 operates autonomously in individual neurons and specifically during the late larval stage.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1982 Feb 4;295(5848):405-7 [6799834.001]
  • [Cites] Development. 2004 Oct;131(20):5167-84 [15459108.001]
  • [Cites] Dev Biol. 1988 Jan;125(1):145-57 [3119399.001]
  • [Cites] Annu Rev Neurosci. 1990;13:183-94 [2183673.001]
  • [Cites] J Neurobiol. 1990 Oct;21(7):1072-84 [1979610.001]
  • [Cites] Development. 1991 Jan;111(1):79-88 [1901786.001]
  • [Cites] Cell. 1993 Jul 2;73(7):1323-37 [8324824.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9475-9 [8415726.001]
  • [Cites] Mol Cell Biol. 1994 Feb;14(2):944-50 [8289834.001]
  • [Cites] Genes Dev. 1994 Jan;8(2):133-46 [8299934.001]
  • [Cites] Development. 1993 Dec;119(4):1251-9 [8306887.001]
  • [Cites] Development. 1994 Jan;120(1):189-97 [8119126.001]
  • [Cites] Development. 1994 Jan;120(1):219-34 [8119129.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5972-6 [8016099.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5625-30 [7890683.001]
  • [Cites] Curr Opin Neurobiol. 1995 Feb;5(1):28-35 [7773002.001]
  • [Cites] Development. 1997 Jan;124(2):461-70 [9053322.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):85-9 [9288972.001]
  • [Cites] Nature. 1997 Dec 4;390(6659):465-71 [9393997.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):F105-50 [9395284.001]
  • [Cites] J Neurosci Res. 1998 Jan 15;51(2):139-46 [9469567.001]
  • [Cites] Genetics. 1998 Feb;148(2):801-13 [9504926.001]
  • [Cites] Science. 1998 Jul 31;281(5377):706-9 [9685266.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2354-70 [9694800.001]
  • [Cites] Mol Cell. 1998 Jul;2(1):109-20 [9702197.001]
  • [Cites] Nature. 1998 Aug 27;394(6696):909-13 [9732876.001]
  • [Cites] Cell. 1998 Sep 4;94(5):585-94 [9741623.001]
  • [Cites] Cell. 1998 Dec 11;95(6):737-40 [9865691.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):98-111 [9887103.001]
  • [Cites] Science. 1999 Feb 26;283(5406):1317-21 [10037600.001]
  • [Cites] Neuron. 1999 Mar;22(3):451-61 [10197526.001]
  • [Cites] Genes Cells. 1999 Feb;4(2):123-34 [10320478.001]
  • [Cites] Dev Biol. 1999 Jun 15;210(2):251-68 [10357889.001]
  • [Cites] Learn Mem. 1998 May-Jun;5(1-2):52-77 [10454372.001]
  • [Cites] Learn Mem. 1998 May-Jun;5(1-2):102-14 [10454375.001]
  • [Cites] Development. 1999 Sep;126(18):4065-76 [10457015.001]
  • [Cites] Neuron. 1999 Sep;24(1):127-41 [10677032.001]
  • [Cites] Neuron. 2000 Mar;25(3):549-61 [10774724.001]
  • [Cites] Neuron. 2000 Dec;28(3):807-18 [11163268.001]
  • [Cites] Neuron. 2002 Feb 14;33(4):529-43 [11856528.001]
  • [Cites] Neuron. 2002 Feb 14;33(4):545-58 [11856529.001]
  • [Cites] Neuron. 2002 Feb 14;33(4):559-71 [11856530.001]
  • [Cites] Development. 2002 Apr;129(8):1839-47 [11934850.001]
  • [Cites] Cell. 2003 Feb 7;112(3):303-15 [12581521.001]
  • [Cites] Neuron. 2003 May 8;38(3):389-401 [12741987.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Neuron. 2004 Sep 2;43(5):663-72 [15339648.001]
  • [Cites] J Comp Neurol. 1987 Jan 22;255(4):548-59 [3819030.001]
  • (PMID = 16437159.001).
  • [ISSN] 0261-4189
  • [Journal-full-title] The EMBO journal
  • [ISO-abbreviation] EMBO J.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / T32 HD007333; United States / NICHD NIH HHS / HD / HD07333
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta; 104625-48-1 / Activins; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / Activin Receptors, Type II; EC 2.7.11.30 / put protein, Drosophila
  • [Other-IDs] NLM/ PMC1383542
  •  go-up   go-down


2. Aslam S, Santha T, Leone A, Wilcox C: Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int; 2006 Dec;70(12):2109-15
Hazardous Substances Data Bank. AMLODIPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
  • Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors.
  • We conclude that hypertensive patients with ESRD receiving HD have evidence of extensive oxidation of lipids, thiols, proteins, and nucleic acids and methylation of arginine that could contribute to CVD.
  • [MeSH-major] Amlodipine / administration & dosage. Angiotensin II Type 1 Receptor Blockers / administration & dosage. Arginine / analogs & derivatives. Calcium Channel Blockers / administration & dosage. Kidney Failure, Chronic / drug therapy. Tetrazoles / administration & dosage. Valine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Pressure / drug effects. Cross-Over Studies. Female. Humans. Hypertension, Renal / drug therapy. Hypertension, Renal / metabolism. Male. Methylation / drug effects. Middle Aged. Oxidative Stress / drug effects. Renal Dialysis. Valsartan

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALSARTAN .
  • Hazardous Substances Data Bank. L-Valine .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kidney Int. 2006 Dec;70(12):2053-5 [17136131.001]
  • (PMID = 17063175.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR020359
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Calcium Channel Blockers; 0 / Tetrazoles; 1J444QC288 / Amlodipine; 30315-93-6 / N,N-dimethylarginine; 80M03YXJ7I / Valsartan; 94ZLA3W45F / Arginine; HG18B9YRS7 / Valine
  •  go-up   go-down


3. Lie PP, Xia W, Wang CQ, Mruk DD, Yan HH, Wong CH, Lee WM, Cheng CY: Dynamin II interacts with the cadherin- and occludin-based protein complexes at the blood-testis barrier in adult rat testes. J Endocrinol; 2006 Dec;191(3):571-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamin II interacts with the cadherin- and occludin-based protein complexes at the blood-testis barrier in adult rat testes.
  • In adult rat testes, blood-testis barrier (BTB) restructuring facilitates the migration of preleptotene spermatocytes from the basal to the adluminal compartment that occurs at stage VIII of the epithelial cycle.
  • Dynamin II, a large GTPase known to be involved in endocytosis, was shown to be a product of Sertoli and germ cells in the testis.
  • By co-immunoprecipitation, dynamin II was shown to associate with occludin, N-cadherin, zonula occludens-1 (ZO-1), beta-catenin, junctional adhesion molecule-A, and p130Cas, but not nectin-3.
  • At the time of germ cell loss from the seminiferous epithelium as a result of adjudin-induced AJ restructuring without disrupting the BTB integrity, a significant decline in the steady-state dynamin II protein level was detected.
  • Interestingly, these changes were also accompanied by a significant increase in the structural interaction of dynamin II with beta-catenin and ZO-1.
  • However, beta-catenin and ZO-1 were 'disengaged' from each other but bound to dynamin II during adjudin-induced AJ restructuring in the testis.
  • The data reported herein suggest that dynamin II may assist the 'disengagement' of beta-catenin from ZO-1 during BTB restructuring.
  • [MeSH-major] Blood-Testis Barrier. Cadherins / metabolism. Dynamin II / metabolism. Membrane Proteins / metabolism. Testis / physiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17170215.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD045908; United States / NICHD NIH HHS / HD / U54 HD029990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1-(2,4-dichlorobenzyl)indazole-3-carbohydrazide; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Hydrazines; 0 / Indazoles; 0 / Membrane Proteins; 0 / Occludin; 0 / Ocln protein, rat; 0 / Phosphoproteins; 0 / Tjp1 protein, rat; 0 / Zonula Occludens-1 Protein; 0 / beta Catenin; 0 / nectins; EC 3.6.5.5 / Dynamin II
  •  go-up   go-down


Advertisement
4. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D: N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int; 2007 Mar;71(6):548-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis.
  • In patients with end-stage renal disease (ESRD) in hemodialysis (HD), levels of NT-proBNP are almost always raised.
  • In ESRD patients undergoing HD, we aimed at (i) identifying the factors that affect levels of NT-proBNP, (ii) determining the effect of HD on NT-proBNP, and (iii) determining the prognostic impact of NT-proBNP.
  • Serum NT-proBNP was measured before and after HD (Elecsys 2010).
  • NT-proBNP levels were markedly elevated (pre-HD 4079 pg/ml, post-HD 2759 pg/ml, P<0.001).
  • Patients with higher concentrations, both pre- and post-HD had an increased mortality rate compared to those with lower concentrations (P=0.007, P=0.002).
  • We found age (P=0.009) and NT-proBNP (pre-HD P=0.007, post-HD P=0.001) predictive of death.
  • Our findings demonstrate that CV disease in terms of LVH and reduced LVEF in addition to 24-h urine production and K(t)/V determine NT-proBNP levels.
  • Post-HD levels of NT-proBNP were lower than pre-HD levels; both predictive of mortality.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cardiovascular Diseases / blood. Cardiovascular Diseases / diagnosis. Cardiovascular Diseases / etiology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Regression Analysis. Risk Factors. Stroke Volume / physiology. Ventricular Dysfunction, Left / blood. Ventricular Dysfunction, Left / diagnosis. Ventricular Dysfunction, Left / etiology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kidney Int. 2007 Mar;71(6):481-3 [17344896.001]
  • (PMID = 17299526.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


5. Chambon JP, Alarcon B, N'Guyen HD, Gaillard R, Pagniez D, Dumont A: [Results of infrainguinal revascularization in patients with end-stage renal disease]. Ann Chir; 2005 Jan;130(1):26-31
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of infrainguinal revascularization in patients with end-stage renal disease].
  • OBJECTIVES: The aim of this retrospective study was to evaluate the efficacy of bypass in patients with endstage renal disease (ESRD) and to determine predictive factors and precise bypass indications.
  • METHOD: Forty one patients with ESRD underwent 50 bypass, 6 limbs were stage II and 44 stage III or IV according to Leriche and Fontaine classification.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Inguinal Canal / blood supply. Inguinal Canal / surgery. Kidney / blood supply. Male. Middle Aged. Morbidity. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664373.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Xu J, Bernuci MP, Lawson MS, Yeoman RR, Fisher TE, Zelinski MB, Stouffer RL: Survival, growth, and maturation of secondary follicles from prepubertal, young, and older adult rhesus monkeys during encapsulated three-dimensional culture: effects of gonadotropins and insulin. Reproduction; 2010 Nov;140(5):685-97
Hazardous Substances Data Bank. ALGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival, growth, and maturation of secondary follicles from prepubertal, young, and older adult rhesus monkeys during encapsulated three-dimensional culture: effects of gonadotropins and insulin.
  • A three-dimensional culture system supports the development of primate preantral follicles to the antral stage with appreciable steroid production.
  • This study assessed i) whether in vitro developmental competence of follicles is age dependent, ii) the role of gonadotropins and insulin in supporting folliculogenesis, and iii) anti-Müllerian hormone (AMH) and vascular endothelial growth factor (VEGF) production by growing follicles.
  • Ovaries were obtained from prepubertal, young, and older adult rhesus macaques.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • Hazardous Substances Data Bank. ALGINIC ACID .
  • Hazardous Substances Data Bank. CALCIUM ALGINATE .
  • Hazardous Substances Data Bank. POTASSIUM ALGINATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1990 Apr;70(4):894-902 [2108185.001]
  • [Cites] J Anim Sci. 1991 Aug;69(8):3321-34 [1894569.001]
  • [Cites] Endocrinology. 1992 Jul;131(1):254-60 [1612003.001]
  • [Cites] J Endocrinol. 1992 Dec;135(3):589-95 [1487710.001]
  • [Cites] Biol Reprod. 1993 Feb;48(2):349-56 [8439624.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1411-8 [8077342.001]
  • [Cites] Endocr J. 1993 Dec;40(6):715-26 [7951542.001]
  • [Cites] Hum Reprod. 1994 Jul;9(7):1237-42 [7962424.001]
  • [Cites] Hum Reprod. 1995 Jul;10(7):1658-66 [8582957.001]
  • [Cites] Endocr Rev. 1996 Apr;17(2):121-55 [8706629.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3722-6 [8855829.001]
  • [Cites] Nat Genet. 1997 Feb;15(2):201-4 [9020850.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):71-106 [9034787.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2135-42 [9215284.001]
  • [Cites] Gynecol Endocrinol. 1997 Dec;11(6):371-81 [9476086.001]
  • [Cites] Hum Reprod. 1998 May;13(5):1292-302 [9647562.001]
  • [Cites] J Reprod Fertil. 1998 May;113(1):19-26 [9713372.001]
  • [Cites] Biol Reprod. 1998 Dec;59(6):1445-53 [9828191.001]
  • [Cites] Maturitas. 1998 Oct 12;30(2):137-42 [9871908.001]
  • [Cites] Hum Reprod. 1999 Jun;14(6):1555-62 [10357975.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 29;234(1-2):87-93 [15836957.001]
  • [Cites] Biol Reprod. 2005 Nov;73(5):942-50 [15987824.001]
  • [Cites] Rev Epidemiol Sante Publique. 2005 Nov;53 Spec No 2:2S37-45 [16471143.001]
  • [Cites] Reprod Biol Endocrinol. 2006;4:16 [16603089.001]
  • [Cites] Hum Reprod. 2006 Sep;21(9):2223-7 [16720622.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2456-68 [16740654.001]
  • [Cites] Clin Chim Acta. 2007 Jan;375(1-2):162-4 [16860302.001]
  • [Cites] Endocrinology. 2007 May;148(5):2301-8 [17255205.001]
  • [Cites] Endocrinology. 2007 May;148(5):2273-81 [17317775.001]
  • [Cites] Zygote. 2007 May;15(2):173-82 [17462110.001]
  • [Cites] Hum Reprod. 2009 Sep;24(9):2264-75 [19520713.001]
  • [Cites] Biol Reprod. 2009 Sep;81(3):587-94 [19474063.001]
  • [Cites] Hum Reprod. 2009 Oct;24(10):2531-40 [19597190.001]
  • [Cites] Hum Reprod Update. 2010 Jan-Feb;16(1):39-50 [19752047.001]
  • [Cites] Fertil Steril. 2010 Mar 15;93(5):1421-9 [19243760.001]
  • [Cites] J Clin Endocrinol Metab. 2010 May;95(5):2306-15 [20200332.001]
  • [Cites] Mol Hum Reprod. 2007 Jun;13(6):361-71 [17416905.001]
  • [Cites] Tissue Eng. 2006 Oct;12(10):2739-46 [17518643.001]
  • [Cites] Soc Reprod Fertil Suppl. 2007;63:327-42 [17566282.001]
  • [Cites] Soc Reprod Fertil Suppl. 2007;63:531-8 [17566297.001]
  • [Cites] Biomaterials. 2007 Oct;28(30):4439-48 [17643486.001]
  • [Cites] Reproduction. 2008 Dec;136(6):703-15 [19074213.001]
  • [Cites] Biol Reprod. 2009 Mar;80(3):432-9 [19005169.001]
  • [Cites] Reprod Fertil Dev. 2009;21(5):679-87 [19486605.001]
  • [Cites] Theriogenology. 2009 Jul 15;72(2):243-50 [19362733.001]
  • [Cites] Biol Reprod. 2000 Jul;63(1):320-7 [10859274.001]
  • [Cites] Mol Hum Reprod. 2000 Aug;6(8):694-8 [10908278.001]
  • [Cites] Mol Cell Endocrinol. 2000 May 25;163(1-2):61-6 [10963875.001]
  • [Cites] Biol Reprod. 2001 Jan;64(1):293-8 [11133686.001]
  • [Cites] Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Dec;14(6):883-900 [11141339.001]
  • [Cites] Reproduction. 2001 May;121(5):647-53 [11427152.001]
  • [Cites] Reproduction. 2001 Dec;122(6):829-38 [11732978.001]
  • [Cites] Arch Med Res. 2001 Nov-Dec;32(6):567-75 [11750732.001]
  • [Cites] J Vet Med Sci. 2002 Sep;64(9):803-6 [12399605.001]
  • [Cites] Hum Reprod. 2002 Nov;17(11):2825-31 [12407033.001]
  • [Cites] Reproduction. 2002 Nov;124(5):601-9 [12416998.001]
  • [Cites] Mol Hum Reprod. 2004 Feb;10(2):77-83 [14742691.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2896-905 [14988387.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):282-90 [15028627.001]
  • [Cites] N Engl J Med. 1972 Dec 28;287(26):1313-7 [4344039.001]
  • [Cites] J Exp Zool. 1974 Oct;190(1):123-7 [4436619.001]
  • [Cites] J Reprod Fertil. 1975 Oct;45(1):83-90 [1195259.001]
  • [Cites] Am J Obstet Gynecol. 1976 Sep 1;126(1):91-4 [961752.001]
  • [Cites] Br J Obstet Gynaecol. 1979 May;86(5):354-63 [465383.001]
  • [Cites] Steroids. 1980 Jul;36(1):53-63 [7414656.001]
  • [Cites] Mol Cell Endocrinol. 1984 May;35(2-3):97-105 [6428947.001]
  • [Cites] Obstet Gynecol. 1984 Sep;64(3 Suppl):73S-80S [6382082.001]
  • (PMID = 20729335.001).
  • [ISSN] 1741-7899
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / RL1 HD058294; United States / NICHD NIH HHS / HD / T32 HD007133-21; United States / NICHD NIH HHS / HD / RL1 HD058293; United States / NCRR NIH HHS / RR / P51 RR000163-51; United States / NICHD NIH HHS / HD / U54 HD018185-25; United States / NCRR NIH HHS / RR / P51 RR000163; United States / NICHD NIH HHS / HD / R01-HD058294; United States / NCRR NIH HHS / RR / RR024926-01; United States / NCRR NIH HHS / RR / RR00163; United States / FIC NIH HHS / TW / D43 TW000668-05; United States / NICHD NIH HHS / HD / U54-HD18185; United States / FIC NIH HHS / TW / D43 TW000668; United States / NICHD NIH HHS / HD / RL1 HD058293-05; United States / NICHD NIH HHS / HD / HD018185-25; United States / NIBIB NIH HHS / EB / PL1 EB008542-01; United States / NIBIB NIH HHS / EB / PL1 EB008542; United States / NCRR NIH HHS / RR / K01 RR000163; United States / NCRR NIH HHS / RR / UL1 RR024926; United States / NICHD NIH HHS / HD / T32 HD007133; United States / NCRR NIH HHS / RR / UL1 RR024926-01; United States / NICHD NIH HHS / HD / RL1 HD058294-01; United States / NIBIB NIH HHS / EB / EB008542-01; United States / NICHD NIH HHS / HD / RL1 HD058294-05; United States / FIC NIH HHS / TW / D43TW000668; United States / NICHD NIH HHS / HD / U54 HD018185; United States / NICHD NIH HHS / HD / HD07133; United States / NIBIB NIH HHS / EB / PL1-EB008542
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alginates; 0 / Hexuronic Acids; 0 / Insulin; 0 / Vascular Endothelial Growth Factor A; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 80497-65-0 / Anti-Mullerian Hormone; 8A5D83Q4RW / Glucuronic Acid; 8C3Z4148WZ / alginic acid; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ NIHMS370551; NLM/ PMC3351200
  •  go-up   go-down


7. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A: Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol; 2006 Jan;78(1):1-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.
  • BACKGROUND: Short course chemotherapy followed by radiotherapy is a standard treatment for early Hodgkin's disease.
  • PATIENTS AND METHODS: From 1980 to 1996, 61 patients with stage I and II supradiaphragmatic Hodgkin's disease were treated with chemotherapy alone at the Royal Marsden Hospital.
  • Twenty patients (83%) relapsed in the initially involved sites of disease and this was the sole site of recurrence in 11 (45%) of patients.
  • Review of detailed imaging data (available in 9 out of 11 patients with recurrences in initial sites of disease) showed that the relapses were always in the initially involved nodes.
  • CONCLUSION: After chemotherapy alone in early stage HD most initial recurrences are nodal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309770.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


8. Yamasaki H, Sandrof MA, Boekelheide K: Suppression of radiation-induced testicular germ cell apoptosis by 2,5-hexanedione pretreatment. I. Histopathological analysis reveals stage dependence of attenuated apoptosis. Toxicol Sci; 2010 Oct;117(2):449-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of radiation-induced testicular germ cell apoptosis by 2,5-hexanedione pretreatment. I. Histopathological analysis reveals stage dependence of attenuated apoptosis.
  • 2,5-Hexanedione (HD) and x-radiation (x-ray) are testicular toxicants, each with a unique cellular target.
  • HD exposure disrupts microtubule function in Sertoli cells, and x-ray exposure causes double-strand breaks in the DNA of germ cells.
  • In this study, adult male F344 rats were exposed to 1% HD in the drinking water for 18 days with or without coexposure to 2 or 5 Gy x-ray 12 h prior to necropsy.
  • Incidence of retained spermatid heads was increased in the HD and coexposure groups.
  • There was a striking stage-dependent attenuation of apoptosis with coexposure compared with x-ray alone.
  • Detailed histopathological analysis revealed a significant suppression of x-ray-induced germ cell apoptosis by HD pretreatment in stages I-VI of the seminiferous cycle, most noticeably at stages II/III.
  • We hypothesize either that subacute HD pretreatment compromises the ability of the Sertoli cells to eliminate x-ray-damaged germ cells or that germ cells are more resistant to x-ray-induced damage, having adapted to a less supportive environment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Soc Exp Biol Med. 2000 Nov;225(2):105-15 [11044252.001]
  • [Cites] Toxicol Sci. 2010 Oct;117(2):457-65 [20616210.001]
  • [Cites] Toxicol Sci. 2004 Jul;80(1):92-100 [15141104.001]
  • [Cites] Biol Reprod. 1983 Aug;29(1):257-70 [6615968.001]
  • [Cites] Toxicol Appl Pharmacol. 1988 Jan;92(1):18-27 [3341024.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Apr;137(2):141-8 [8661338.001]
  • [Cites] J Androl. 1996 Jul-Aug;17(4):394-402 [8889702.001]
  • [Cites] Radiat Res. 1997 Apr;147(4):457-67 [9092926.001]
  • [Cites] Endocrinology. 1997 May;138(5):2081-8 [9112408.001]
  • [Cites] Tissue Cell. 1997 Aug;29(4):487-93 [9281847.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):852-8 [9927315.001]
  • [Cites] Endocrinology. 1999 Apr;140(4):1709-17 [10098507.001]
  • [Cites] Ann N Y Acad Sci. 1952 Nov 20;55(4):548-73 [13139144.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(34):6-8 [15784812.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):249-56 [17065434.001]
  • [Cites] Toxicol Pathol. 2007 Aug;35(5):719-27 [17763286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8315-20 [18544648.001]
  • [Cites] Toxicol Pathol. 2008 Jun;36(4):552-9 [18467684.001]
  • [Cites] Toxicol Sci. 2010 Oct;117(2):466-74 [20616204.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:125-47 [12471174.001]
  • (PMID = 20616207.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES013660; United States / NIEHS NIH HHS / ES / 5 P42 ES013660
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hexanones; 0 / Radiation-Protective Agents; 110-13-4 / 2,5-hexanedione
  • [Other-IDs] NLM/ PMC2940404
  •  go-up   go-down


9. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D: Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol; 2006 Jun;29(3):246-51
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
  • OBJECTIVE: To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC).
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Analysis. Topotecan / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755177.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-35629; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Lamm BM, Gottlieb HD, Paley D: A two-stage percutaneous approach to charcot diabetic foot reconstruction. J Foot Ankle Surg; 2010 Nov-Dec;49(6):517-22
MedlinePlus Health Information. consumer health - Diabetic Foot.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage percutaneous approach to charcot diabetic foot reconstruction.
  • Feet were operated on at various stages of Charcot deformity: Eichenholtz stage I (1 foot), Eichenholtz stage II (6 feet), and Eichenholtz stage III (4 feet).
  • [MeSH-minor] Achilles Tendon / surgery. Adult. Aged. Equinus Deformity / surgery. Female. Fluoroscopy. Foot Bones / surgery. Foot Joints / radiography. Foot Joints / surgery. Humans. Male. Middle Aged. Muscle, Skeletal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20864361.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Cano AE, Neil AK, Kang JY, Barnabas A, Eastwood JB, Nelson SR, Hartley I, Maxwell D: Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. Am J Gastroenterol; 2007 Sep;102(9):1990-7
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
  • OBJECTIVES: The aim of this study was to determine the prevalence of gastrointestinal symptoms in patients with end-stage renal disease undergoing hemodialysis (HD) or peritoneal dialysis (PD) treatment.
  • METHODS: Patients undergoing HD or chronic ambulatory PD in the Department of Renal Medicine of our hospital were asked to complete a locally validated Rome II questionnaire.
  • Patients on HD and their outpatient controls also completed the Hospital Anxiety and Depression Scale.
  • RESULTS: A total of 148 patients with end-stage renal disease (HD 100, PD 48) completed the study.
  • Among HD patients and their outpatient controls, the differences appeared to be unrelated to anxiety or depression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anxiety / complications. Depression / complications. Female. Humans. Male. Middle Aged. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2008 May;103(5):1317-8 [18477364.001]
  • (PMID = 17511755.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Moriyama T, Matsumoto T, Hirakawa K, Ikeda H, Tsuruya K, Hirakata H, Iida M: Helicobacter pylori status and esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis. J Gastroenterol; 2010 May;45(5):515-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori status and esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis.
  • OBJECTIVES: The aim of this study was to elucidate the impact of Helicobacter pylori infection on esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis (HD).
  • METHODS: An upper endoscopy and the (13)C-urea breath test were performed in 198 patients on maintenance HD.
  • RESULTS: The upper endoscopy revealed that gastric erosion was the most frequent (58%) type of esophagogastroduodenal mucosal lesion, followed by duodenal erosion (18%), gastric ulcer (14%), gastroesophageal reflux disease (10%), and duodenal ulcer (7%).
  • The time duration after the introduction of HD was significantly longer and serum pepsinogen I/II ratio was significantly higher in H. pylori-negative patients than in H. pylori-positive patients.
  • CONCLUSIONS: The most common mucosal lesion observed in our study cohort, all of whom were patients on maintenance HD, was gastric erosion.
  • The high prevalence of this type of lesion may be explained partly by the cure of H. pylori infection during the clinical course of maintenance HD.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Endoscopy, Digestive System. Female. Humans. Male. Middle Aged. Prevalence. Young Adult


13. Alexander JM, Leveno KJ, Rouse DJ, Landon MB, Gilbert S, Spong CY, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O, Gabbe SG, National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU): Comparison of maternal and infant outcomes from primary cesarean delivery during the second compared with first stage of labor. Obstet Gynecol; 2007 Apr;109(4):917-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of maternal and infant outcomes from primary cesarean delivery during the second compared with first stage of labor.
  • OBJECTIVE: To compare maternal and neonatal outcomes when primary cesarean delivery is performed in the second stage of labor compared with the first stage.
  • RESULTS: A total of 11,981 cesarean deliveries were available for analysis: 9,265 were performed in the first stage and 2,716 in the second stage.
  • Cesarean deliveries performed in the second stage were associated with longer operative times, epidural analgesia, chorioamnionitis, and higher birth weight (all P<.001).
  • The maternal composite index was slightly increased in women undergoing cesarean delivery in the second stage of labor, primarily due to uterine atony, uterine incision extension, and incidental cystotomy.
  • CONCLUSION: Cesarean delivery in the second stage of labor is associated with slightly increased maternal but not neonatal composite morbidity.
  • LEVEL OF EVIDENCE: II.
  • [MeSH-major] Apgar Score. Cesarean Section / adverse effects. Labor Stage, First. Labor Stage, Second. Obstetric Labor Complications / epidemiology. Pregnancy Outcome
  • [MeSH-minor] Adult. Birth Injuries / epidemiology. Female. Humans. Infant Mortality. Infant, Newborn. Intensive Care, Neonatal. Intraoperative Complications. Intubation. Morbidity. Pregnancy. Seizures / epidemiology

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Childbirth Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400854.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD21410; United States / NICHD NIH HHS / HD / HD21414; United States / NICHD NIH HHS / HD / HD27860; United States / NICHD NIH HHS / HD / HD27861; United States / NICHD NIH HHS / HD / HD27869; United States / NICHD NIH HHS / HD / HD27905; United States / NICHD NIH HHS / HD / HD27915; United States / NICHD NIH HHS / HD / HD27917; United States / NICHD NIH HHS / HD / HD34116; United States / NICHD NIH HHS / HD / HD34122; United States / NICHD NIH HHS / HD / HD34136; United States / NICHD NIH HHS / HD / HD34208; United States / NICHD NIH HHS / HD / HD34210; United States / NICHD NIH HHS / HD / HD36801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


14. Huang HD, Lin FJ, Li XJ, Wang LR, Jiang GR: Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy. Chin Med J (Engl); 2010 Nov;123(22):3238-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy.
  • BACKGROUND: Genetic variability in the renin-angiotensin-aldosterone system may modify renal responses to injury and disease progression.
  • The angiotensin I-converting enzyme (ACE) gene insertion/deletion (I/D), the angiotensinogen (AGT) gene, M235T, the aldosterone synthase (CYP11B2) gene, C-344T, and the angiotensin II type 1 receptor (AT1R) gene, A1166C, have been shown to be associated with IgA nephropathy (IgAN) and its progression.
  • We determined the presence of these polymorphisms in 130 Chinese patients with IgAN, including 47 patients with end-stage renal disease (ESRD) and 120 healthy Chinese subjects, to assess their impact on the susceptibility to disease and the liability of progression to ESRD.
  • [MeSH-minor] Adult. Angiotensinogen / genetics. Asian Continental Ancestry Group / genetics. Cytochrome P-450 CYP11B2 / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Peptidyl-Dipeptidase A / genetics. Polymorphism, Genetic / genetics. Receptor, Angiotensin, Type 1 / genetics

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21163122.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptor, Angiotensin, Type 1; 11002-13-4 / Angiotensinogen; EC 1.14.15.4 / Cytochrome P-450 CYP11B2; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


15. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr: Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine; 2010 Jul 12;28(31):5135-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
  • Plasmodium falciparum Liver Stage Antigen 1 (LSA-1) is a pre-erythrocytic stage antigen.
  • We describe the first Phase I/II study of this recombinant LSA-NRC protein formulated with either the AS01 or AS02 adjuvant system.
  • We conducted an open-label Phase I/II study.
  • Thirty-six healthy malaria-naïve adults received one of four formulations by intra-deltoid injection on a 0 and 1 month schedule; low dose (LD) LSA-NRC/AS01:10microg LSA-NRC/0.5ml AS01 (n=5), high dose (HD) LSA-NRC/AS01: 50microg LSA-NRC/0.5ml AS01 (n=13); LD LSA-NRC/AS02: 10microg LSA-NRC/0.5ml AS02 (n=5) and HD LSA-NRC/AS02: 50microg LSA-NRC/0.5ml AS02 (n=13).
  • In contrast, the HD LSA-NRC/AS01 and HD LSA-NRC/AS02 group subjects had fewer LSA-1-specific CD4+ T cells, and minimal to no IFN-gamma responses.
  • [MeSH-minor] Adjuvants, Immunologic / pharmacology. Adult. Antibodies, Protozoan / blood. Antibody Formation. Female. Humans. Immunity, Cellular. Immunity, Humoral. Immunization Schedule. Immunization, Secondary. Interferon-gamma / immunology. Interleukin-2 / immunology. Male. Parasitemia / immunology. Plasmodium falciparum / immunology. Recombinant Proteins / immunology. Sporozoites / immunology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier Ltd.
  • (PMID = 19737527.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Protozoan; 0 / Antigens, Protozoan; 0 / IL2 protein, human; 0 / Interleukin-2; 0 / Malaria Vaccines; 0 / Recombinant Proteins; 0 / liver stage-specific antigen, Plasmodium; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


16. Eppig JJ, O'Brien MJ, Wigglesworth K, Nicholson A, Zhang W, King BA: Effect of in vitro maturation of mouse oocytes on the health and lifespan of adult offspring. Hum Reprod; 2009 Apr;24(4):922-8
MedlinePlus Health Information. consumer health - Assisted Reproductive Technology.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of in vitro maturation of mouse oocytes on the health and lifespan of adult offspring.
  • All metaphase II oocytes were fertilized in vitro and transferred at the 2-cell stage to the oviducts of pseudo-pregnant foster mothers for development to term.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Brain Res. 1999 Nov 15;105(2):207-17 [10563494.001]
  • [Cites] Biol Reprod. 2008 Oct;79(4):618-23 [18562706.001]
  • [Cites] Development. 2000 Oct;127(19):4195-202 [10976051.001]
  • [Cites] Behav Res Methods Instrum Comput. 2001 Aug;33(3):392-7 [11591071.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):241-8 [11988333.001]
  • [Cites] Biol Reprod. 2003 May;68(5):1682-6 [12606400.001]
  • [Cites] Physiol Genomics. 2003 May 13;13(3):227-39 [12746467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1595-600 [14747652.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5880-5 [15079084.001]
  • [Cites] Nature. 1965 Oct 23;208(5008):349-51 [4957259.001]
  • [Cites] J Reprod Fertil. 1977 Sep;51(1):1-15 [335057.001]
  • [Cites] J Exp Zool. 1983 Jun;226(3):481-5 [6684147.001]
  • [Cites] Dev Biol. 1984 Apr;102(2):493-7 [6706011.001]
  • [Cites] Biol Reprod. 1996 Jan;54(1):197-207 [8838017.001]
  • [Cites] Fertil Steril. 2005 May;83(5):1461-5 [15866585.001]
  • [Cites] Reprod Biomed Online. 2005 May;10(5):593-9 [15949216.001]
  • [Cites] Reproduction. 2005 Nov;130(5):599-601 [16264090.001]
  • [Cites] Hum Reprod. 2006 Jun;21(6):1508-13 [16449308.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1277-91 [16996508.001]
  • [Cites] Adv Exp Med Biol. 2007;591:72-83 [17176555.001]
  • [Cites] Reprod Fertil Dev. 2007;19(1):43-52 [17389134.001]
  • [Cites] Mol Reprod Dev. 2007 Sep;74(9):1149-56 [17474101.001]
  • [Cites] Hum Reprod. 2007 Oct;22(10):2768-75 [17725990.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19351-6 [18042717.001]
  • [Cites] Biol Reprod. 2008 Feb;78(2):299-306 [17989357.001]
  • [Cites] Semin Reprod Med. 2008 Mar;26(2):162-74 [18302108.001]
  • [Cites] J Physiol. 2008 Apr 15;586(8):2231-44 [18308825.001]
  • [Cites] Hum Reprod. 2008 May;23(5):1138-44 [18346995.001]
  • [Cites] Biol Reprod. 2000 Jun;62(6):1526-35 [10819752.001]
  • (PMID = 19151027.001).
  • [ISSN] 1460-2350
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD21970
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Culture Media
  • [Other-IDs] NLM/ PMC2721727
  •  go-up   go-down


17. Remien RH, Higgins JA, Correale J, Bauermeister J, Dubrow R, Bradley M, Steward WT, Seal DW, Sikkema KJ, Kerndt PR, Mayer KH, Truong HM, Casey CY, Ehrhardt AA, Morin SF: Lack of understanding of acute HIV infection among newly-infected persons-implications for prevention and public health: The NIMH Multisite Acute HIV Infection Study: II. AIDS Behav; 2009 Dec;13(6):1046-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of understanding of acute HIV infection among newly-infected persons-implications for prevention and public health: The NIMH Multisite Acute HIV Infection Study: II.
  • Over time and after the acute stage of infection, many participants acquired understanding of AHI from varied sources, including the Internet, HIV-infected friends, and health clinic employees.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4 [16988643.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):213-21 [17146375.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1037-45 [19495954.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1054-60 [19504178.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1068-74 [19504179.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):446-53 [16010168.001]
  • [Cites] Am J Public Health. 2001 Mar;91(3):400-5 [11236404.001]
  • [Cites] Am J Prev Med. 2001 Aug;21(2):84-92 [11457627.001]
  • [Cites] AIDS. 2004 May 21;18(8):1179-86 [15166533.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1057-66 [15247559.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1873-83 [15872202.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1061-7 [19517225.001]
  • (PMID = 19533323.001).
  • [ISSN] 1573-3254
  • [Journal-full-title] AIDS and behavior
  • [ISO-abbreviation] AIDS Behav
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / P30 MH062246; United States / NIMH NIH HHS / MH / L30 MH084308; United States / NIAID NIH HHS / AI / P30AI42853; United States / NIMH NIH HHS / MH / P30 MH062294; United States / NIMH NIH HHS / MH / P30 MH052776; United States / NIMH NIH HHS / MH / P30 MH043520; United States / NIMH NIH HHS / MH / P30MH052776; United States / NIMH NIH HHS / MH / P30MH058107; United States / NICHD NIH HHS / HD / R24 HD047879; United States / NIMH NIH HHS / MH / P30 MH043520-21; United States / NIMH NIH HHS / MH / P30MH062512; United States / NIMH NIH HHS / MH / P30 MH058107; United States / NIAID NIH HHS / AI / U01 AI043638; United States / NIMH NIH HHS / MH / P30MH062294; United States / NIMH NIH HHS / MH / MH084308-01; United States / NIMH NIH HHS / MH / P30 MH062512; United States / NIMH NIH HHS / MH / MH043520-21; United States / NIAID NIH HHS / AI / P30 AI042853; United States / NIMH NIH HHS / MH / L30 MH084308-01; United States / NIAID NIH HHS / AI / AI43638; United States / NIMH NIH HHS / MH / P30MH043520; United States / NIMH NIH HHS / MH / P30MH062246
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS128605; NLM/ PMC2787764
  •  go-up   go-down


18. Mühlau M, Gaser C, Wohlschläger AM, Weindl A, Städtler M, Valet M, Zimmer C, Kassubek J, Peinemann A: Striatal gray matter loss in Huntington's disease is leftward biased. Mov Disord; 2007 Jun 15;22(8):1169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Striatal gray matter loss in Huntington's disease is leftward biased.
  • In Huntington's disease (HD), the distribution of pathological changes throughout the brain is incompletely understood.
  • We performed magnetic resonance imaging and a voxel-based asymmetry analysis in 44 right-handed HD gene carriers (presymptomatic, n = 5; stage I, n = 28; stage II, n = 11) and 44 right-handed healthy controls.
  • Further analyses showed no indication of asymmetry in presymptomatic HD patients but an increase in asymmetry in the course of the HD stages under examination.
  • Our study demonstrates and discusses leftward-biased gray matter loss in HD.
  • [MeSH-major] Brain / pathology. Corpus Striatum / pathology. Functional Laterality / physiology. Huntington Disease / pathology
  • [MeSH-minor] Adult. Aged. Cognition Disorders / diagnosis. Cognition Disorders / epidemiology. Female. Humans. Male. Middle Aged. Nerve Degeneration / epidemiology. Nerve Degeneration / pathology. Neuropsychological Tests. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394246.001).
  • [ISSN] 0885-3185
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Nishio T, Takamura N, Nishii R, Tokunaga J, Yoshimoto M, Kawai K: Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition. Nephrol Dial Transplant; 2008 Jul;23(7):2304-10
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose is to elucidate the differences in the binding capacities of sites I and II of HSA between pre-haemodialysis (HD) and post-HD in patients with end-stage renal disease.
  • METHODS: We evaluated free fractions of site probes, (14)C-warfarin (site I) and (14)C-diazepam (site II), by ultrafiltration in serum between pre-HD and post-HD.
  • RESULTS: The concentrations of HSA and FFA increased significantly (post-HD/pre-HD ratio: 1.18 +/- 0.10, 5.46 +/- 4.91), the concentrations of IS and HA decreased significantly (post-HD/pre-HD ratio: 0.69 +/- 0.10, 0.33 +/- 0.15) and CMPF concentrations did not alter significantly (post-HD/pre-HD ratio: 0.97 +/- 0.12, P = 0.471).
  • The free fractions of (14)C-warfarin decreased in all 14 patients at site I at post-HD compared to pre-HD (post-HD/pre-HD ratio: 0.59 +/- 0.13).
  • The free fractions of (14)C-diazepam at site II remarkably decreased in 10 of 14 patients (post-HD/pre-HD ratio: 0.61 +/- 0.17) and unexpectedly increased in 4 (post-HD/pre-HD ratio: 1.08 +/- 0.06) post-HD compared to pre-HD.
  • In these four patients, when we investigated the influences of these variation factors on the reduction of the binding capacities of site II, [FFA]/[HSA] increased significantly post-HD, compared to pre-HD (post-HD/pre-HD ratio: 6.91 +/- 6.58). ([FFA]/[HSA] ratios of the 4 patients were from 1.22 to 3.55, the highest for the 14 patients post-HD, but the ratios of the other 10 were below 1.2 post-HD.
  • ) CONCLUSION: The binding capacity of site II was unexpectedly decremented by the effects of the remarkable elevation of FFA.
  • Therefore, monitoring the binding capacity of site II in HD is important for patients with end-stage renal disease in the efficacious administration plan using the binding inhibition of HSA.
  • [MeSH-minor] Adult. Aged. Barbiturates / metabolism. Binding Sites. Carbon Radioisotopes / metabolism. Diazepam / metabolism. Diuretics / metabolism. Fatty Acids, Nonesterified / metabolism. Female. Furans / metabolism. Furosemide / metabolism. Hippurates / metabolism. Humans. Indican / metabolism. Male. Middle Aged. Propionates / metabolism. Protein Binding. Treatment Outcome. Warfarin / metabolism

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18390890.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid; 0 / Barbiturates; 0 / Carbon Radioisotopes; 0 / Diuretics; 0 / Fatty Acids, Nonesterified; 0 / Furans; 0 / Hippurates; 0 / Propionates; 0 / Serum Albumin; 5Q7ZVV76EI / Warfarin; 7LXU5N7ZO5 / Furosemide; 9T08RAL174 / bucolome; N187WK1Y1J / Indican; Q3JTX2Q7TU / Diazepam; TE0865N2ET / hippuric acid
  •  go-up   go-down


20. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1545-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
  • Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT.
  • We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT.
  • Phase II consisted of etoposide (2 g/m2).
  • Eleven out of nineteen patients with B-cell lymphoma received rituximab.
  • The estimated 4-year PFS and overall survival (OS) were 72.2% and 47.6% in HD patients and 70.3% and 69.4% in NHL patients, respectively.
  • Factors predicting OS were response to conventional salvage therapy and stage prior to salvage therapy.
  • Three prognostic subgroups were defined according to the score determined by stage prior to initiation of salvage chemotherapy, remission duration prior to salvage (refractory/early relapse vs. late relapse) and response to salvage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966265.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


21. Moalli PA, Shand SH, Zyczynski HM, Gordy SC, Meyn LA: Remodeling of vaginal connective tissue in patients with prolapse. Obstet Gynecol; 2005 Nov;106(5 Pt 1):953-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissue of 15 premenopausal women with less than stage II prolapse (controls) was compared with that of 62 women with prolapse divided according to their menopausal status.
  • LEVEL OF EVIDENCE: II-2.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Estrogen Replacement Therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260512.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD 045590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrillar Collagens; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


22. McCampbell AS, Walker CL, Broaddus RR, Cook JD, Davies PJ: Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat. Lab Invest; 2008 Jun;88(6):615-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In rodents, a brief neonatal exposure of the developing reproductive tract to the xenoestrogen, diethylstilbestrol (DES) reprograms developing tissues to increase susceptibility to tumorigenesis in adult animals, including uterine adenocarcinoma.
  • Progression from a normal endometrium to carcinoma occurs via the intermediate stage of endometrial hyperplasia.
  • The endometrium of DES-exposed rats overexpressed IGF-II and insulin receptor substrate-1 (IRS-1) and exhibited elevated Akt expression and activation (as judged by phosphorylation) and mTOR signaling (phosphorylation of S6) compared to vehicle-treated endometrium.
  • [MeSH-major] Endometrial Hyperplasia / chemically induced. Genetic Predisposition to Disease. Insulin-Like Growth Factor I / metabolism. Signal Transduction
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Animals. Animals, Newborn. Carcinogens. Diethylstilbestrol. Female. Insulin Receptor Substrate Proteins. Insulin-Like Growth Factor II / metabolism. Ki-67 Antigen / drug effects. Ki-67 Antigen / metabolism. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / metabolism. RNA, Neoplasm / analysis. RNA, Neoplasm / isolation & purification. Rats. Rats, Mutant Strains. Ribosomal Protein S6 Kinases / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18427555.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NIEHS NIH HHS / ES / ES08263; United States / NICHD NIH HHS / HD / HD46282; United States / NCI NIH HHS / CA / R25-CA57730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carcinogens; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Irs1 protein, rat; 0 / Ki-67 Antigen; 0 / RNA, Neoplasm; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II; 731DCA35BT / Diethylstilbestrol; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases
  •  go-up   go-down


23. Sosa CG, Althabe F, Belizán JM, Buekens P: Risk factors for postpartum hemorrhage in vaginal deliveries in a Latin-American population. Obstet Gynecol; 2009 Jun;113(6):1313-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Active management of the third stage of labor, multiparity, and low birth weight were found to be protective factors.
  • CONCLUSION: Many of the risk factors for immediate postpartum hemorrhage in this South American population are related to complications of the second and third stage of labor.
  • LEVEL OF EVIDENCE: II.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Aug;15(4):206-8 [7834703.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Apr;100(4):327-33 [8494833.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1996 May;36(2):152-4 [8798302.001]
  • [Cites] Arch Gynecol Obstet. 1997;259(4):179-87 [9271837.001]
  • [Cites] Gynecol Obstet Invest. 1998;46(1):31-3 [9692338.001]
  • [Cites] Am J Obstet Gynecol. 1999 Sep;181(3):669-74 [10486482.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Jun;93(3):220-4 [16626718.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1929-40 [18450604.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Jul;70(1):89-97 [10884537.001]
  • [Cites] J Perinat Med. 2003;31(3):209-15 [12825476.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):166-72 [15262350.001]
  • [Cites] J Obstet Gynaecol Br Commonw. 1970 May;77(5):424-6 [5310621.001]
  • [Cites] Obstet Gynecol. 1991 Jan;77(1):69-76 [1984230.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1991 Jan 30;38(2):119-24 [1995380.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1993 Jan;48(1):15-8 [8449256.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1994 Oct;29(10):582-5, 635 [7712868.001]
  • (PMID = 19461428.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD040477-05; United States / FIC NIH HHS / TW / TW005492-06; United States / FIC NIH HHS / TW / D43 TW005492-06; United States / NICHD NIH HHS / HD / HD040477-05; United States / FIC NIH HHS / TW / D43 TW005492; United States / FIC NIH HHS / TW / R01 TW007600; United States / NICHD NIH HHS / HD / U01HD040477; United States / FIC NIH HHS / TW / TW05492; United States / NICHD NIH HHS / HD / U01 HD040477
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS125772; NLM/ PMC2730945
  •  go-up   go-down


24. De Diego-Balaguer R, Couette M, Dolbeau G, Dürr A, Youssov K, Bachoud-Lévi AC: Striatal degeneration impairs language learning: evidence from Huntington's disease. Brain; 2008 Nov;131(Pt 11):2870-81
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Striatal degeneration impairs language learning: evidence from Huntington's disease.
  • We studied 13 pre-symptomatic gene-carriers and 22 early stage patients of Huntington's disease (pre-HD), both characterized by a progressive degeneration of the striatum and 21 late stage patients Huntington's disease (18 stage II, two stage III and one stage IV) where cortical degeneration accompanies striatal degeneration.
  • When presented with a simplified artificial language where words and rules could be extracted, early stage Huntington's disease patients (stage I) were impaired in the learning test, demonstrating a greater impairment in rule than word learning compared to the 20 age- and education-matched controls.
  • Huntington's disease patients at later stages were impaired both on word and rule learning.
  • [MeSH-major] Corpus Striatum / pathology. Huntington Disease / psychology. Language. Learning
  • [MeSH-minor] Acoustic Stimulation / methods. Adult. Aged. Attention. Cognition Disorders / etiology. Cognition Disorders / psychology. Disease Progression. Female. Heterozygote. Humans. Language Tests. Magnetic Resonance Imaging / methods. Male. Memory, Short-Term. Middle Aged. Neuropsychological Tests. Semantics. Severity of Illness Index. Transfer (Psychology)

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychologia. 2006;44(2):275-88 [15964035.001]
  • [Cites] Behav Brain Res. 2006 Jan 30;166(2):189-96 [16153716.001]
  • [Cites] Nat Neurosci. 2006 Apr;9(4):562-8 [16501567.001]
  • [Cites] Nat Rev Neurosci. 2006 Jun;7(6):464-76 [16715055.001]
  • [Cites] Rev Neurol (Paris). 2006 Jun;162(6-7):721-8 [16840980.001]
  • [Cites] Curr Pharm Des. 2006;12(21):2701-20 [16842168.001]
  • [Cites] Neuroimage. 2006 Oct 1;32(4):1562-75 [16875847.001]
  • [Cites] J Cogn Neurosci. 2006 Sep;18(9):1555-69 [16989555.001]
  • [Cites] Neuropsychologia. 2007 Jan 28;45(2):305-20 [16978666.001]
  • [Cites] Neuroimage. 2007 Jun;36(2):431-40 [17462915.001]
  • [Cites] Psychol Sci. 2007 May;18(5):387-91 [17576276.001]
  • [Cites] Psychol Rev. 2007 Jul;114(3):632-56 [17638499.001]
  • [Cites] Neuroimage. 2007 Aug 1;37(1):8-17 [17560794.001]
  • [Cites] Am J Psychiatry. 2007 Sep;164(9):1428-34 [17728429.001]
  • [Cites] Cognition. 2007 Nov;105(2):247-99 [17083927.001]
  • [Cites] Hum Brain Mapp. 2007 Nov;28(11):1089-97 [17133392.001]
  • [Cites] PLoS One. 2007;2(11):e1175 [18000546.001]
  • [Cites] J Exp Psychol Learn Mem Cogn. 2008 Jan;34(1):80-96 [18194056.001]
  • [Cites] Neuropsychologia. 2008 Apr;46(5):1391-400 [18242648.001]
  • [Cites] Cereb Cortex. 2008 Jul;18(7):1496-505 [17947346.001]
  • [Cites] Neurology. 2000 Mar 14;54(5):1117-23 [10720284.001]
  • [Cites] Neuroscience. 2000;96(3):451-74 [10717427.001]
  • [Cites] J Psycholinguist Res. 2001 Jan;30(1):37-69 [11291183.001]
  • [Cites] Nature. 2001 Jun 21;411(6840):953-6 [11418860.001]
  • [Cites] J Psycholinguist Res. 2001 May;30(3):321-38 [11523277.001]
  • [Cites] Cognition. 2002 Feb;83(1):B13-23 [11814489.001]
  • [Cites] J Neurosci. 2002 Apr 1;22(7):2541-9 [11923419.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1815-28 [12135972.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6756-65 [12151555.001]
  • [Cites] Neuron. 2002 Jul 18;35(2):371-81 [12160754.001]
  • [Cites] Science. 2002 Oct 18;298(5593):604-7 [12202684.001]
  • [Cites] Cognition. 2003 Mar;87(2):B69-77 [12590043.001]
  • [Cites] Neurology. 2003 May 27;60(10):1615-20 [12771251.001]
  • [Cites] Cognition. 2003 Nov;90(1):91-117 [14597271.001]
  • [Cites] Neuroimage. 2003 Nov;20 Suppl 1:S8-17 [14597292.001]
  • [Cites] J Int Neuropsychol Soc. 2003 Nov;9(7):1041-52 [14738285.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):213-20 [14742591.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(1):181-9 [14750976.001]
  • [Cites] Arch Clin Neuropsychol. 2004 Mar;19(2):203-14 [15010086.001]
  • [Cites] Ann Neurol. 2004 Apr;55(4):522-9 [15048891.001]
  • [Cites] Brain Lang. 2004 Jun;89(3):524-30 [15120543.001]
  • [Cites] Int J Lang Commun Disord. 2004 Jul-Sep;39(3):401-22 [15204448.001]
  • [Cites] Neurology. 1981 Oct;31(10):1333-5 [6125919.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77 [2932539.001]
  • [Cites] Cortex. 1986 Mar;22(1):11-32 [2940074.001]
  • [Cites] Neurology. 1988 Mar;38(3):341-7 [2964565.001]
  • [Cites] J Neurophysiol. 1989 Apr;61(4):814-32 [2723722.001]
  • [Cites] Brain Lang. 1989 Nov;37(4):628-42 [2479447.001]
  • [Cites] Acta Neurol Belg. 1990;90(4):207-17 [2124031.001]
  • [Cites] Neurology. 1991 Jul;41(7):1117-23 [1829794.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12(6):1217-22 [1763757.001]
  • [Cites] Neuroscience. 1995 Sep;68(2):273-85 [7477940.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] J Commun Disord. 1996 May-Jun;29(3):183-97 [8799853.001]
  • [Cites] Science. 1996 Dec 13;274(5294):1926-8 [8943209.001]
  • [Cites] Neuropsychology. 1997 Apr;11(2):272-81 [9110333.001]
  • [Cites] Science. 1997 Jul 18;277(5324):376-80 [9219696.001]
  • [Cites] Psychol Rev. 1998 Jan;105(1):158-73 [9450375.001]
  • [Cites] J Neurosci. 1998 Mar 1;18(5):1841-7 [9465008.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 May;57(5):369-84 [9596408.001]
  • [Cites] Brain. 1998 Jul;121 ( Pt 7):1343-55 [9679785.001]
  • [Cites] Stroke. 1999 Jan;30(1):100-8 [9880396.001]
  • [Cites] Brain. 1999 Sep;122 ( Pt 9):1667-78 [10468506.001]
  • [Cites] Cereb Cortex. 2004 Dec;14(12):1302-9 [15166103.001]
  • [Cites] Trends Cogn Sci. 2005 Feb;9(2):83-9 [15668101.001]
  • [Cites] Neuroreport. 2005 Feb 8;16(2):111-5 [15671857.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):584-96 [15659423.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):873-6 [15729344.001]
  • [Cites] Neuroimage. 2005 Apr 15;25(3):958-68 [15808996.001]
  • [Cites] Brain. 2005 May;128(Pt 5):1155-67 [15788544.001]
  • [Cites] Cognition. 2005 Sep;97(2):B25-34 [16226557.001]
  • [Cites] Clin Sci (Lond). 2006 Jan;110(1):73-88 [16336206.001]
  • (PMID = 18842608.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ HALMS345589; NLM/ PMC2773249
  •  go-up   go-down


25. Fitzgerald MP, Weber AM, Howden N, Cundiff GW, Brown MB, Pelvic Floor Disorders Network: Risk factors for anal sphincter tear during vaginal delivery. Obstet Gynecol; 2007 Jan;109(1):29-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on univariable analysis, a woman with a sphincter tear was more likely to be older, to be white, to have longer gestation or prolonged second stage of labor, to have a larger infant (birth weight/head circumference), or an infant who was in occiput posterior position, or to have an episiotomy or operative delivery.
  • LEVEL OF EVIDENCE: II.
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Labor Presentation. Labor Stage, Second. Pregnancy. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197584.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K24 DK068389; United States / NICHD NIH HHS / HD / U01 HD41249; United States / NICHD NIH HHS / HD / U10 HD41248; United States / NICHD NIH HHS / HD / U10 HD41250; United States / NICHD NIH HHS / HD / U10 HD41261; United States / NICHD NIH HHS / HD / U10 HD41263; United States / NICHD NIH HHS / HD / U10 HD41267; United States / NICHD NIH HHS / HD / U10 HD41268; United States / NICHD NIH HHS / HD / U10 HD41269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


26. Kennedy CM, Peterson LB, Galask RP: Erosive vulvar lichen planus: a cohort at risk for cancer? J Reprod Med; 2008 Oct;53(10):781-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 1 had stage II vulvar SCC after treatment for stage IIB cervical cancer, and 2 with oral LP had subsequent diagnoses of oral or esophageal SCC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Comorbidity. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004404.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 1K23 HD045769
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


27. Smakotina SA, Trubnikova OA, Anan'ko IuA, Barbarash OL: [Effect of perindopril on cognitive functions in young and middle aged patients with hypertensive disease]. Kardiologiia; 2008;48(9):28-33
MedlinePlus Health Information. consumer health - High Blood Pressure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of perindopril on cognitive functions in young and middle aged patients with hypertensive disease].
  • We studied 40 men aged 26 - 59 years (mean age 49.0 +/- 1.9 years) with hypertensive disease (HD) and found that therapy based on the use of angiotensin converting enzyme inhibitor perindopril in young and middle aged patients with stage I and II HD appeared to be not only one of effective methods of correction of elevated arterial pressure (AP) but also of associated with it cognitive abnormalities.
  • Favorable effects of perindopril in relation to parameters of cognitive functions in patients with HD allows to rate perindopril not only as effective and safe hypotensive preparation but as remedy exerting cerebroprotective effect.
  • [MeSH-minor] Adult. Blood Pressure / drug effects. Blood Pressure Monitoring, Ambulatory. Female. Follow-Up Studies. Humans. Male. Middle Aged. Psychometrics / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991817.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; Y5GMK36KGY / Perindopril
  •  go-up   go-down


28. Potapov EV, Hennig F, Wagner FD, Volk HD, Sodian R, Hausmann H, Lehmkuhl HB, Hetzer R: Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. Eur J Cardiothorac Surg; 2005 May;27(5):899-905
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In patients with inotrope-dependent end-stage heart failure the timely application of the most suitable treatment, i.e. heart transplantation, implantation of a ventricular assist device or conservative treatment, is a key issue for therapeutic success.
  • METHODS: Seventy-six inotrope-dependent patients with end-stage heart failure were enrolled.
  • The patients were retrospectively divided into groups with regard to the following end-points: Group I-deterioration into cardiogenic shock after an initially stable clinical course (n=26); Group II-stable clinical course without deterioration into cardiogenic (n=41); Group III-weaning from inotropic support (n=9).
  • RESULTS: One day before cardiogenic shock occurred, BNP, NT-proBNP and E-selectin were significantly elevated in group I compared with group II.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / blood. C-Reactive Protein / analysis. Dobutamine / administration & dosage. Dobutamine / therapeutic use. Dopamine / administration & dosage. Dopamine / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Enoximone / administration & dosage. Enoximone / therapeutic use. Epidemiologic Methods. Epinephrine / administration & dosage. Epinephrine / therapeutic use. Female. Humans. Male. Middle Aged. Natriuretic Peptide, Brain / blood. Nerve Tissue Proteins / blood. Norepinephrine / administration & dosage. Norepinephrine / therapeutic use. Peptide Fragments / blood. Prognosis. Shock, Cardiogenic / blood. Shock, Cardiogenic / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848333.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / E-Selectin; 0 / Natriuretic Peptides; 0 / Nerve Tissue Proteins; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain; 3S12J47372 / Dobutamine; 9007-41-4 / C-Reactive Protein; C7Z4ITI7L7 / Enoximone; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


29. Liang WJ, Qiu F, Hong MH, Guo L, Qin HD, Liu QC, Zhang XS, Mai HQ, Xiang YQ, Min HQ, Zeng YX: [Differentially expressed genes between upward and downward progressing types of nasopharyngeal carcinoma]. Ai Zheng; 2008 May;27(5):460-5
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Upward (local growth and invasion of the base of skull), downward (distant metastasis) and mixed progressing types of nasopharygeal carcinoma (NPC) have been observed when the disease progress to middle-late stage.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Metastasis. Reverse Transcriptase Polymerase Chain Reaction. Skull Base Neoplasms / genetics. Skull Base Neoplasms / metabolism. Skull Base Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479593.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.11.1.- / iodothyronine deiodinase type II; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


30. Zamotaev IuN, Enikeev AKh: [Evaluation of psychophysiological status and performance ability in patients with hypertensive disease employed under strained working conditions]. Klin Med (Mosk); 2009;87(12):44-7
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of psychophysiological status and performance ability in patients with hypertensive disease employed under strained working conditions].
  • The aim of this work was to study psychophysiological functions in HD subjects during strenuous conveyor-belt work.
  • It involved 225 participants of whom 195 presented with different stages of HD.
  • Group 1 (n = 65) included patients with prehypertension, group 2 (n = 69) with stage 1 HD, group 3 (n = 61) with stage II HD.
  • It was shown that performance efficiency of the conveyor-belt workers decreased with increasing HD severity.
  • [MeSH-minor] Adolescent. Adult. Blood Pressure / physiology. Female. Humans. Male. Severity of Illness Index. Task Performance and Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20135886.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


31. Roth EB, Jeffe DB, Margenthaler JA, Aft RL: Method of breast cancer presentation and depressed mood 1 year after diagnosis in women with locally advanced disease. Ann Surg Oncol; 2009 Jun;16(6):1637-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Method of breast cancer presentation and depressed mood 1 year after diagnosis in women with locally advanced disease.
  • BACKGROUND: Differences in psychological outcomes of breast cancer patients with locally advanced disease who presented with abnormal screening mammograms or palpable mass have not been reported.
  • METHODS: We interviewed 120 women with clinical stage II/III breast cancer enrolled onto a prospective phase 2 clinical trial at diagnosis and 1 year after diagnosis, inquiring about demographics, depressive symptoms, social support, and perceived risk of disease recurrence.
  • RESULTS: A significant interaction was observed between presentation method and change in depressed mood among 86 women without disease progression who completed both interviews.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Behav Med. 1999 Summer;21(3):201-9 [10626025.001]
  • [Cites] Psychooncology. 1999 May-Jun;8(3):264-7 [10390739.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] J Psychosom Res. 1989;33(1):1-5 [2926697.001]
  • (PMID = 19360452.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / P30 CA91842; United States / NICHD NIH HHS / HD / T32 HD052266
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS562260; NLM/ PMC3982328
  •  go-up   go-down


32. Kovács AF, Mose S, Böttcher HD, Bitter K: Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol; 2005 Jan;181(1):26-34
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: 94 patients (Table 1) with primary resectable squamous cell carcinoma of the oral cavity and oropharynx (UICC stage I 14%, II 15%, III 18%, IV 53%; Table 2) were treated with a multimodality therapy program consisting of neoadjuvant intra-arterial high-dose chemotherapy (cisplatin 150 mg/m(2) with parallel systemic sodium thiosulfate 9 g/m(2) for neutralization), followed by surgery of the primary and neck, and postoperative concurrent radiation and chemotherapy with weekly docetaxel (20-30 mg/m(2); Table 3).
  • RESULTS: At a median follow-up of 4 years, the 5-year survival rate for all 94 patients was 80%, and disease-free survival was 73% (Figures 1 and 2).
  • Among patients with advanced disease (stage III and IV), survival was 83 and 59%, respectively (Figure 4).
  • CONCLUSIONS: Concurrent radiation and chemotherapy with weekly docetaxel is a feasible postoperative treatment in a multimodality approach to oral and oropharyngeal cancer, resulting in high overall and disease-free survival.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Head / pathology. Humans. Infusions, Intravenous. Injections, Intra-Arterial. Male. Middle Aged. Neck / pathology. Neck Dissection. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Care. Radiotherapy Dosage. Survival Analysis. Thiosulfates / administration & dosage. Thiosulfates / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660190.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Striuk RI, Brytkova IaV, Bukhonkina IuM, Pavlova LN: [Clinical efficacy of antihypertensive therapy of pregnant women with arterial hypertension with long acting nifedipine and bisoprolol]. Kardiologiia; 2008;48(4):29-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Examination and treatment with nifedipine SR/GITS 30 mg/day and bisoprolol 2,5 - 5 mg/day was carried out in 21 patients with stage II hypertensive disease (HD) during trimester II of pregnancy.
  • In patients with stage II HD this parameter significantly exceeded that of control group.
  • [MeSH-minor] Adult. Delayed-Action Preparations. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Pregnancy. Receptors, Adrenergic, beta / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447837.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Calcium Channel Blockers; 0 / Delayed-Action Preparations; 0 / Receptors, Adrenergic, beta; I9ZF7L6G2L / Nifedipine; Y41JS2NL6U / Bisoprolol
  •  go-up   go-down


34. El-Shafey EM, El-Nagar GF, Selim MF, El-Sorogy HA, Sabry AA: Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis? Clin Exp Nephrol; 2008 Oct;12(5):370-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The etiology of hemodialysis (HD)-induced hypotension and hypertension remains speculative.
  • We examined the possible role of intradialytic changes of ET-1 in the pathogenesis of hypotension and rebound hypertension during HD.
  • METHODS: The present study included 45 patients with end-stage renal disease (ESRD) on regular HD.
  • They were divided according to their hemodynamic status during HD into three groups (group I had stable intradialytic hemodynamics, group II had dialysis-induced hypotension, and group III had rebound hypertension during HD).
  • Pulse and blood pressure were monitored before, during (every half hour), and after HD session.
  • ET-1 level was measured at the beginning, middle, and end of HD.
  • RESULTS: Pre-dialysis levels of ET-1 were significantly higher in dialysis patients compared to the controls (P < 0.001); however, they were comparable in the three HD groups.
  • The post-dialysis ET-1 level was not changed significantly in group I compared with predialysis values (14.49 +/- 2.04 vs. 14.33 +/- 2.23 pg/ml; P = NS), while the ET-1 concentration decreased significantly in group II and increased in group III in comparison to predialysis values (8.56 +/- 1.44 vs. 11.75 +/- 2.51; 16.39 +/- 3.12 vs. 11.93 +/- 2.11 pg/ml, respectively; P < 0.001).
  • CONCLUSION: Altered ET-1 levels may be involved in the pathogenesis of rebound hypertension and hypotension during HD.
  • [MeSH-minor] Adult. Blood Pressure / physiology. Case-Control Studies. Egypt. Female. Heart Rate / physiology. Humans. Male. Middle Aged. Prospective Studies


35. Gimaev RKh, Ruzov VI, Razin VA, Boluchevskiĭ DN, Verushkina AS, Siapukova AA: [Effect of lipid metabolism disturbances on electrophysiologic heart remodeling in patients with hypertensive disease]. Klin Med (Mosk); 2009;87(11):30-3
MedlinePlus Health Information. consumer health - High Blood Pressure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of lipid metabolism disturbances on electrophysiologic heart remodeling in patients with hypertensive disease].
  • The aim of the study was to evaluate effect of disturbed lipid metabolism on dispersion of QT interval, signal-averaged ECG characteristics, and cardiac rhythm variability as indicators of electrophysiological remodeling of myocardium in patients with HD.
  • The study included 111 patients aged 30-73 (mean 51.4 +/- 10.7) years with stage I-II HD.
  • [MeSH-minor] Adult. Aged. Blood Pressure / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Heart Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143562.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


36. Handa VL, Cundiff G, Chang HH, Helzlsouer KJ: Female sexual function and pelvic floor disorders. Obstet Gynecol; 2008 May;111(5):1045-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study population included 301 adult women seeking outpatient gynecologic and urogynecologic care.
  • Stage III-IV prolapse was significantly associated with infrequent orgasm (P=.02), but other sexual complaints were not more common with increasing prolapse stage.
  • LEVEL OF EVIDENCE: II.

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fertil Steril. 2002 Apr;77 Suppl 4:S42-8 [12007901.001]
  • [Cites] Obstet Gynecol. 2002 Feb;99(2):281-9 [11814510.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):751-6 [15467535.001]
  • [Cites] Obstet Gynecol. 1995 Apr;85(4):483-7 [7898820.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1323-33 [9447413.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):103-13 [16021067.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jan;17(1):14-7 [15971004.001]
  • [Cites] J Sex Med. 2004 Jul;1(1):40-8 [16422982.001]
  • [Cites] Am J Obstet Gynecol. 2006 Nov;195(5):e1-4 [17074540.001]
  • [Cites] Obstet Gynecol. 2007 Apr;109(4):831-40 [17400843.001]
  • [Cites] Climacteric. 2007 Apr;10(2):132-42 [17453861.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jul;197(1):88.e1-6 [17618771.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jul;197(1):101.e1-6 [17618777.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD004014 [17636742.001]
  • [Cites] Am J Obstet Gynecol. 2007 Dec;197(6):629.e1-6 [18060957.001]
  • [Cites] J Sex Marital Ther. 2002 Oct-Dec;28(5):389-97 [12378841.001]
  • [Cites] J Sex Marital Ther. 2001 Jul-Sep;27(4):339-51 [11441518.001]
  • [CommentIn] Obstet Gynecol. 2008 May;111(5):1037-8 [18448731.001]
  • (PMID = 18448734.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K23 HD045806; United States / NICHD NIH HHS / HD / K23 HD045806-04; United States / NICHD NIH HHS / HD / K23HD045806
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS114870; NLM/ PMC2746737
  •  go-up   go-down


37. Perry SL, O'Shea SI, Byrne S, Szczech LA, Ortel TL: A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. Thromb Haemost; 2006 Dec;96(6):750-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-molecular-weight heparins undergo renal elimination, and therefore the proper dosing in hemodialysis (HD) patients is unclear.
  • It was the objective of this study to evaluate the pharmacokinetic (PK) parameters of dalteparin in patients receiving chronic HD for end-stage renal disease.
  • We performed a multidose PK study with prophylactic doses of dalteparin in twelve HD patients.
  • Dalteparin 5,000 IU was administered subcutaneously daily for four consecutive days, with HD performed on day 2 and day 4.
  • ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr);.
  • From this pilot PK study, we have determined initial PK parameters for dalteparin in HD patients.
  • Future studies to evaluate the PK parameters of dalteparin in patients receiving chronic HD may have to use weight-based dosing and will need to be performed over a longer period of time.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Body Weight. Drug Administration Schedule. Drug Monitoring. Factor Xa Inhibitors. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139369.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K12 RR17630-03; United States / NIDDK NIH HHS / DK / K23 DK02724-01A1; United States / NCRR NIH HHS / RR / M01-RR-30; United States / NCBDD CDC HHS / DD / U18DD00014; United States / NHLBI NIH HHS / HL / U54-HL077878
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Factor Xa Inhibitors; S79O08V79F / Dalteparin
  •  go-up   go-down


38. Ripperger T, Tröger HD, Schmidtke J: The genetic message of a sudden, unexpected death due to thoracic aortic dissection. Forensic Sci Int; 2009 May 30;187(1-3):1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, for at-risk relatives of the deceased, it could be of great benefit to be alerted to the potential heritable aetiology, because early diagnosis of the latent stage of the disease would allow preventive management.
  • We report here on three cases to underline the practical relevance of (i) documentation of relevant information for differential diagnosis of TAAD-associated disorders, (ii) storage of unfixed tissue samples for subsequent molecular genetic testing, and most importantly (iii) the information of relatives at risk.
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Marfan Syndrome / diagnosis. Marfan Syndrome / genetics. Microfilament Proteins / analysis. Molecular Biology. Mutation. Protein-Serine-Threonine Kinases / analysis. Receptors, Transforming Growth Factor beta / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285815.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / fibrillin; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


39. Tang H, Ross A, Capel B: Expression and functional analysis of Gm114, a putative mammalian ortholog of Drosophila bam. Dev Biol; 2008 Jun 1;318(1):73-81
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In male germ cells, expression of Gm114 begins at 12.5-13.5 days post coitum (dpc), the stage in mice when germ cells cease proliferation and begin differentiation into prospermatogonia.
  • In the adult testis, Gm114 is highly expressed in differentiated spermatocytes and spermatids but not in undifferentiated spermatogonia, strongly suggesting that, similar to Bam, GM114 plays an important role in mammalian germ line stem cell self-renewal and differentiation.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6;129-Kiz<tm1Cpl>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Feb 25;287(5457):1489-93 [10688798.001]
  • [Cites] Dev Biol. 1994 Jun;163(2):331-40 [8200475.001]
  • [Cites] Genetics. 2000 Aug;155(4):1809-19 [10924476.001]
  • [Cites] Reproduction. 2001 Mar;121(3):347-54 [11226060.001]
  • [Cites] Dev Biol. 2001 Dec 1;240(1):212-22 [11784057.001]
  • [Cites] Dev Cell. 2002 May;2(5):537-47 [12015962.001]
  • [Cites] Gene. 2002 Oct 16;299(1-2):195-204 [12459267.001]
  • [Cites] Genome Res. 2003 Mar;13(3):476-84 [12618378.001]
  • [Cites] Science. 2003 Aug 29;301(5637):1239-41 [12947200.001]
  • [Cites] Dev Biol. 2003 Oct 1;262(1):1-15 [14512014.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1786-91 [14561403.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):73-7 [9288969.001]
  • [Cites] Development. 1997 Sep;124(18):3651-62 [9342057.001]
  • [Cites] Development. 1997 Nov;124(21):4361-71 [9334284.001]
  • [Cites] Dev Biol. 2004 Dec 1;276(1):158-71 [15531371.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):171-8 [15668175.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):179-84 [15668176.001]
  • [Cites] Dev Biol. 2005 Jul 1;283(1):215-25 [15893302.001]
  • [Cites] Nature. 2005 Aug 18;436(7053):1030-4 [16107850.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):141-6 [16049683.001]
  • [Cites] Biol Reprod. 2006 Feb;74(2):314-21 [16237148.001]
  • [Cites] RNA. 2006 May;12(5):775-89 [16540694.001]
  • [Cites] Dev Biol. 2006 Jun 1;294(1):161-7 [16564520.001]
  • [Cites] PLoS Biol. 2006 Jun;4(6):e187 [16700629.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9524-9 [16740658.001]
  • [Cites] Mech Dev. 2006 Jun;123(6):440-9 [16806845.001]
  • [Cites] Science. 2007 Apr 20;316(5823):402-4 [17446390.001]
  • [Cites] Mol Reprod Dev. 2007 Jul;74(7):912-21 [17219433.001]
  • [Cites] Sex Dev. 2007;1(2):127-37 [18391523.001]
  • [Cites] Curr Biol. 2003 Dec 2;13(23):2065-72 [14653996.001]
  • [Cites] Development. 2004 Mar;131(6):1365-75 [14973292.001]
  • [Cites] Biol Reprod. 2004 May;70(5):1286-91 [14695910.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):647-52 [15156142.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):653-9 [15156143.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):981-6 [15182671.001]
  • [Cites] Genetics. 2004 Jun;167(2):707-23 [15238523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11695-700 [15289605.001]
  • [Cites] Development. 2004 Oct;131(20):4895-905 [15459096.001]
  • [Cites] Genes Dev. 1990 Dec;4(12B):2242-51 [2279698.001]
  • [Cites] Genesis. 2000 Feb;26(2):116-7 [10686602.001]
  • (PMID = 18423593.001).
  • [ISSN] 1095-564X
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD039963; United States / PHS HHS / / 303 5136; United States / NICHD NIH HHS / HD / R01 HD039963-05; United States / NICHD NIH HHS / HD / HD039963-05; United States / NICHD NIH HHS / HD / HD039963-06; United States / NICHD NIH HHS / HD / HD039963-07; United States / NICHD NIH HHS / HD / R01 HD039963-06; United States / NICHD NIH HHS / HD / R01 HD039963-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / Gm114 protein, mouse; 0 / Proteins; 0 / bam protein, Drosophila
  • [Other-IDs] NLM/ NIHMS53179; NLM/ PMC2480617
  •  go-up   go-down


40. Bittel DC, Kibiryeva N, Butler MG: Expression of 4 genes between chromosome 15 breakpoints 1 and 2 and behavioral outcomes in Prader-Willi syndrome. Pediatrics; 2006 Oct;118(4):e1276-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The larger, type I (TI) deletion involves breakpoint 1, which is close to the centromere, whereas the smaller, type II (TII) deletion involves breakpoint 2, located approximately 500 kilobases distal to breakpoint 1.
  • We previously presented the first assessment of clinical differences in individuals with Prader-Willi syndrome categorized as having type I or II deletions.
  • Understanding the influence of gene expression on behavioral and cognitive characteristics in humans is in the early stage of research development.
  • [MeSH-minor] Adolescent. Adult. Cognition Disorders / etiology. Cognition Disorders / genetics. Female. Gene Expression Profiling. Humans. Male. Obsessive-Compulsive Disorder / etiology. Obsessive-Compulsive Disorder / genetics. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Prader-Willi syndrome.
  • MedlinePlus Health Information. consumer health - Prader-Willi Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Child Psychol Psychiatry. 2005 Oct;46(10 ):1089-96 [16178933.001]
  • [Cites] Genome Res. 2001 Jan;11(1):98-111 [11156619.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2001;2:153-75 [11701647.001]
  • [Cites] Expert Rev Mol Med. 2005 Jul 25;7(14):1-20 [16038620.001]
  • [Cites] Am J Ment Retard. 1999 Jan;104(1):67-77 [9972835.001]
  • [Cites] Pediatrics. 2004 Mar;113(3 Pt 1):565-73 [14993551.001]
  • [Cites] Endocrinologist. 2000 Jul;10(4 Suppl 1):3S-16S [27570435.001]
  • [Cites] J Child Psychol Psychiatry. 1996 Nov;37(8):995-1002 [9119946.001]
  • [Cites] Arch Gen Psychiatry. 1989 Nov;46(11):1006-11 [2684084.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8844-9 [11438699.001]
  • [Cites] Am J Hum Genet. 2003 Oct;73(4):967-71 [14508710.001]
  • [Cites] Am J Med Genet. 1997 Jul 11;71(1):106-10 [9215778.001]
  • [Cites] Am J Hum Genet. 1989 Jul;45(1):140-6 [2741944.001]
  • [Cites] Am J Hum Genet. 2003 Oct;73(4):898-925 [14508708.001]
  • [Cites] Am J Med Genet. 1990 Mar;35(3):319-32 [2309779.001]
  • [Cites] Clin Genet. 2005 Jan;67(1):47-52 [15617548.001]
  • [Cites] Semin Clin Neuropsychiatry. 1996 Apr;1(2):142-147 [10320413.001]
  • [Cites] J Intellect Disabil Res. 2001 Aug;45(Pt 4):317-25 [11489053.001]
  • [Cites] Arch Gen Psychiatry. 1989 Nov;46(11):1012-6 [2510699.001]
  • [Cites] J Med Genet. 1997 Nov;34(11):917-23 [9391886.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1994 Winter;6(1):23-9 [8148633.001]
  • [Cites] J Intellect Disabil Res. 2000 Feb;44 ( Pt 1):25-30 [10711647.001]
  • [Cites] Am J Med Genet. 1997 Feb 11;68(4):433-40 [9021017.001]
  • (PMID = 16982806.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD030329; United States / NICHD NIH HHS / HD / R01 HD041672; United States / NICHD NIH HHS / HD / P01 HD30329; United States / NICHD NIH HHS / HD / R01 HD41672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CYFIP1 protein, human; 0 / Membrane Proteins; 0 / Microtubule-Associated Proteins; 0 / NIPA1 protein, human; 0 / NIPA2 protein, human; 0 / RNA, Messenger; 0 / TUBGCP5 protein, human
  •  go-up   go-down


41. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • In 8 cases (44.44%) forage associated with IES was performed as the initial treatment option and 6 of these cases were found to be in Ficat stage II (75%), 1 was found to be in stage III (12.55%) and another in stage IV (12.5%).
  • In 2 cases, the central decompression technique was used (Simple Forage); both were in Ficat stage II.
  • In the other 8 cases, a total hip arthroplasty (THA) was chosen as the initial treatment option, with 3 of these patients in Ficat stage III and 5 in Ficat stage IV.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • We considered that in Ficat stage III and IV arthroplasty (THA) was the better option.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement, Hip. Decompression, Surgical. Electric Stimulation Therapy. Female. Glucocorticoids / adverse effects. Humans. Male. Middle Aged. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


42. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


43. Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V: Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma; 2005 Dec;46(12):1715-20
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients.
  • Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13% of cases of stage I-II Hodgkin lymphoma (HD).
  • It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH).
  • The comparison of IDH vs SDH can only be made in early and intermediate stages (I-II), such a comparison is not possible for advanced stages (III-IV).
  • This study retrospectively compared two groups of 1013 patients with stage I-II SDH and 101 patients with IDH (10%).
  • These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma.
  • In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95% CI, 1.3-3.4; p = 0.003).
  • After controlling for age, sex, stage, histology, B-symptoms and involvement of 3 LNA, the adjusted hazard ratio was 1.25 (95% CI, 0.65-2.4; p = 0.51) so that IDH was no longer associated with a statistically significant treatment failure rate.
  • [MeSH-major] Hodgkin Disease / physiopathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Diaphragm. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263573.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Qin J, Tsai MJ, Tsai SY: Essential roles of COUP-TFII in Leydig cell differentiation and male fertility. PLoS One; 2008 Sep 26;3(9):e3285
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chicken Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII; also known as NR2F2), is an orphan nuclear receptor of the steroid/thyroid hormone receptor superfamily.
  • Homozygous adult male mutants are defective in testosterone synthesis, and administration of testosterone could largely rescue the mutant defects.
  • Notably, the rescued results also provide the evidence that the major function of adult Leydig cell is to synthesize testosterone.
  • Further phenotypic analysis reveals that Leydig cell differentiation is arrested at the progenitor cell stage in the testes of null mice.
  • On the other hand, when COUP-TFII is deleted in the adult stage after Leydig cells are well differentiated, there are no obvious defects in reproduction and Leydig cell function.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Recent Prog Horm Res. 2002;57:75-101 [12017557.001]
  • [Cites] Mol Endocrinol. 2001 Jan;15(1):184-200 [11145749.001]
  • [Cites] Biol Reprod. 2003 Apr;68(4):1087-97 [12606453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10546-51 [12920187.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):47-74 [11420130.001]
  • [Cites] Biol Reprod. 2001 Sep;65(3):660-71 [11514326.001]
  • [Cites] Endocrinology. 2001 Dec;142(12):5342-50 [11713234.001]
  • [Cites] Biol Reprod. 2002 Apr;66(4):966-75 [11906915.001]
  • [Cites] Dev Biol. 2002 Apr 15;244(2):305-18 [11944939.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):5058-64 [12959969.001]
  • [Cites] Endocrinology. 2004 Mar;145(3):1453-63 [14645113.001]
  • [Cites] Int Rev Cytol. 2004;233:181-241 [15037365.001]
  • [Cites] Nat Genet. 2004 May;36(5):528-33 [15107851.001]
  • [Cites] Physiol Rev. 1971 Jan;51(1):1-22 [4926414.001]
  • [Cites] Endocrinology. 1974 Nov;95(5):1380-4 [4426294.001]
  • [Cites] Nature. 1989 Jul 13;340(6229):163-6 [2739739.001]
  • [Cites] Endocrinology. 1990 Jul;127(1):488-90 [2361482.001]
  • [Cites] Endocr Rev. 1994 Oct;15(5):574-626 [7843069.001]
  • [Cites] J Endocrinol. 1996 May;149(2):191-7 [8708529.001]
  • [Cites] Endocr Rev. 1997 Apr;18(2):229-40 [9101138.001]
  • [Cites] Eur J Biochem. 1997 Oct 1;249(1):39-44 [9363751.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1037-49 [10215630.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10835-43 [15572686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17294-9 [15569941.001]
  • [Cites] Int J Androl. 2004 Dec;27(6):335-42 [15595952.001]
  • [Cites] Development. 2005 May;132(9):2179-89 [15829524.001]
  • [Cites] Nature. 2005 May 5;435(7038):98-104 [15875024.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2299-308 [15890675.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16351-6 [16251273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2719-24 [16467141.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):137-45 [16728330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6293-8 [17404209.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e102 [17590085.001]
  • [Cites] Genesis. 2007 Dec;45(12):768-75 [18064676.001]
  • [Cites] J Cell Biol. 2000 May 29;149(5):1019-26 [10831606.001]
  • [Cites] Biol Reprod. 2000 Oct;63(4):1115-23 [10993834.001]
  • [Cites] Dev Biol. 2000 Nov 1;227(1):169-82 [11076685.001]
  • [Cites] Endocrinology. 2003 Jan;144(1):84-93 [12488333.001]
  • (PMID = 18818749.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R37 HD017379; United States / NICHD NIH HHS / HD / HD17379; United States / NHLBI NIH HHS / HL / HL076448; United States / NIDDK NIH HHS / DK / DK45641; United States / NIDDK NIH HHS / DK / P01 DK059820; United States / NIDDK NIH HHS / DK / P01DK59820; United States / NIDDK NIH HHS / DK / R01 DK045641; United States / NICHD NIH HHS / HD / U54 HD028934; United States / NICHD NIH HHS / HD / U54-HD28934; United States / NHLBI NIH HHS / HL / R01 HL076448; United States / NICHD NIH HHS / HD / R01 HD017379; United States / NIDDK NIH HHS / DK / R37 DK045641
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / COUP Transcription Factor II; 3XMK78S47O / Testosterone; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2553269
  •  go-up   go-down


45. Alexander JM, Leveno KJ, Hauth JC, Landon MB, Gilbert S, Spong CY, Varner MW, Caritis SN, Meis P, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O, Gabbe SG, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU): Failed operative vaginal delivery. Obstet Gynecol; 2009 Nov;114(5):1017-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare maternal and neonatal outcomes in women undergoing second-stage cesarean delivery after a trial of operative vaginal delivery with those in women undergoing second-stage cesarean delivery without such an attempt.
  • METHODS: This study is a secondary analysis of the women who underwent second-stage cesarean delivery.
  • RESULTS: Of 3,189 women who underwent second-stage cesarean delivery, operative vaginal delivery was attempted in 640.
  • LEVEL OF EVIDENCE: II.

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Childbirth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2581-9 [15598960.001]
  • [Cites] BMJ. 2006 Sep 23;333(7569):613-4 [16990297.001]
  • [Cites] Obstet Gynecol. 2007 Apr;109(4):917-21 [17400854.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1709-14 [10580069.001]
  • [Cites] Br Med J. 1950 Jul 1;2(4669):18-21 [15426793.001]
  • [Cites] BMJ. 2004 May 29;328(7451):1302-5 [15166069.001]
  • [Cites] Obstet Gynecol. 1986 Dec;68(6):779-83 [3785789.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):200-4 [9024114.001]
  • [Cites] Am J Obstet Gynecol. 1953 Apr;65(4):889-96 [13030623.001]
  • [Cites] Br Med J. 1953 Oct 31;2(4843):955-7 [13094080.001]
  • (PMID = 20168101.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD36801; United States / NICHD NIH HHS / HD / HD27861; United States / NICHD NIH HHS / HD / UG1 HD027869; United States / NICHD NIH HHS / HD / HD27905; United States / NICHD NIH HHS / HD / U10 HD034116-14; United States / NICHD NIH HHS / HD / UG1 HD034116; United States / NICHD NIH HHS / HD / HD27869; United States / NICHD NIH HHS / HD / HD34136; United States / NICHD NIH HHS / HD / U10 HD034136; United States / NICHD NIH HHS / HD / HD27860; United States / NICHD NIH HHS / HD / UG1 HD027915; United States / NICHD NIH HHS / HD / HD21414; United States / NICHD NIH HHS / HD / U10 HD027905; United States / NICHD NIH HHS / HD / UG1 HD034208; United States / NICHD NIH HHS / HD / U10 HD034116; United States / NICHD NIH HHS / HD / HD34122; United States / NICHD NIH HHS / HD / HD034116-14; United States / NICHD NIH HHS / HD / HD34210; United States / NICHD NIH HHS / HD / HD21410; United States / NICHD NIH HHS / HD / U10 HD027869; United States / NICHD NIH HHS / HD / U10 HD027917; United States / NICHD NIH HHS / HD / HD34116; United States / NICHD NIH HHS / HD / U10 HD034122; United States / NICHD NIH HHS / HD / U10 HD027915; United States / NICHD NIH HHS / HD / U10 HD027860; United States / NICHD NIH HHS / HD / U10 HD034208; United States / NICHD NIH HHS / HD / HD34208; United States / NICHD NIH HHS / HD / HD27915; United States / NICHD NIH HHS / HD / HD27917; United States / NICHD NIH HHS / HD / U10 HD021410; United States / NICHD NIH HHS / HD / U10 HD036801; United States / NICHD NIH HHS / HD / U01 HD036801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS250462; NLM/ PMC3075422
  •  go-up   go-down


46. Barbarash OL, Rutkovskaia NV, Smakotina SA, Chesnokova IuL, Bazdyrev EV, Cherniavskaia EIu, Kudriavtseva IA: [Pulmonary involvement in patients with hypertensive disease]. Kardiologiia; 2010;50(3):31-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary involvement in patients with hypertensive disease].
  • METHODS: Parameters of spirometry, body plethysmography, and pulmonary diffusion capacity were measured in 46 patients (age 35-60 years, 40 men, 6 women) with stage I-II hypertensive disease (HD) without bronchial and pulmonary diseases, systolic dysfunction of left ventricular myocardium, obesity, current or past smoking.
  • RESULTS: Increase of severity of HD and elevation of average values of arterial pressure (AP) was associated with mixed type worsening of parameters of pulmonary ventilation capacity.
  • CONCLUSION: The data presented allow to suggest that lungs can stand as target organ in hypertensive disease.
  • [MeSH-minor] Adult. Blood Pressure. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Plethysmography. Prognosis. Spirometry. Vital Capacity

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459403.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


47. El Kelany MA, Maklad SS, El Fouhil DF, El Etreby EA, Saleh LH, El Sheikh NA: Immunomodulatory effects of secondary hyperparathyroidism on circulating CD4+ and CD8+ T-lymphocytes in chronic renal failure patients. Egypt J Immunol; 2009;16(2):71-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunomodulatory effects of parathyroid hormone (PTH) in patients with end stage renal disease (ESRD) is controversial.
  • This study was carried out to investigate the effect of PTH levels on the circulating CD4+, CD8+ T cell counts (%) in patients with chronic renal failure (CRF) on regular hemodialysis ((HD).
  • The study included 22 patients with serum levels of PTH < 300 pg/ml (group 1), 18 patients with PTH > 300 pg/ml (group II) and 10 age and sex matched normal controls (group III).
  • The mean (%) of total lymphocyte, CD4+, CD8+ and CD4\CD8 ratio of group I were (81.68+/- 9.38), (52.00+/-6.24), (27.13+/- 6.31) and (1.99+/-0.42) respectively, as compared to (73.83+/-13.30), (46.05+/-8.59), (23.05+/-4.63) and (2.03+/-0.41) respectively in group II.
  • Values of group I and II were significantly (P<0.001) lower than controls (88.50 +/- 6.02), (63.30 +/- 6.44), (36.80 +/- 6.44) and (1.76+/-0.36) respectively.
  • In group II, the reduction was significantly (P<0.001) prominent in patients with high PTH levels, with significant inverse correlations (P<0.001) between PTH and % of total lymphocyte (r= -0.93), CD4+ (r= -0.74) and CD8+ % (r=-0.69).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22059355.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Parathyroid Hormone; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


48. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T: 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial; 2010 Jun;14(3):240-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
  • Tsubakihara, presents the Japanese guidelines entitled "Guidelines for Renal Anemia in Chronic Kidney Disease."
  • These guidelines replace the "2004 JSDT Guidelines for Renal Anemia in Chronic Hemodialysis Patients," and contain new, additional guidelines for peritoneal dialysis (PD), non-dialysis (ND), and pediatric chronic kidney disease (CKD) patients.
  • In other words, renal anemia is clearly identified as an "endocrine disease."
  • We have also emphasized that renal anemia may be treated not only with ESA therapy but also with appropriate iron supplementation and the improvement of anemia associated with chronic disease, which is associated with inflammation, and inadequate dialysis, another major cause of renal anemia.
  • In Chapter 2, which discusses the target Hb levels in ESA therapy, the guidelines establish different target levels for hemodialysis (HD) patients than for PD and ND patients, for two reasons: (i) In Japanese HD patients, Hb levels following hemodialysis rise considerably above their previous levels because of ultrafiltration-induced hemoconcentration; and (ii) as noted in the 2004 guidelines, although 10 to 11 g/dL was optimal for long-term prognosis if the Hb level prior to the hemodialysis session in an HD patient had been established at the target level, it has been reported that, based on data accumulated on Japanese PD and ND patients, in patients without serious cardiovascular disease, higher levels have a cardiac or renal function protective effect, without any safety issues.
  • However, with the results of, for example, the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) study in mind, the guidelines establish an upper limit of 12 g/dL for patients with serious cardiovascular disease or patients for whom the attending physician determines high Hb levels would not be appropriate.
  • However, if the maximum dose of darbepoetin alfa that can currently be used in HD and PD patients were to be used, then the majority of poor responders would be rescued.
  • Blood transfusions are attributed to the difficulty of managing renal anemia not only in HD patients, but also in end-stage ND patients who respond poorly to ESAs.
  • [MeSH-minor] Adult. Child. Erythropoietin / administration & dosage. Erythropoietin / biosynthesis. Erythropoietin / therapeutic use. Female. Hematinics / administration & dosage. Hematinics / therapeutic use. Hemoglobins / metabolism. Humans. Japan. Male

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20609178.001).
  • [ISSN] 1744-9987
  • [Journal-full-title] Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • [ISO-abbreviation] Ther Apher Dial
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hematinics; 0 / Hemoglobins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


49. Ghosh S, Feingold E, Dey SK: Etiology of Down syndrome: Evidence for consistent association among altered meiotic recombination, nondisjunction, and maternal age across populations. Am J Med Genet A; 2009 Jul;149A(7):1415-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We genotyped each family with a set of STR markers using PCR and characterized the stage of origin of nondisjunction and the recombination pattern of maternal chromosome 21 during oogenesis.
  • Our sample contains 107 maternal meiosis I errors and 31 maternal meiosis II errors and we subsequently stratified them with respect to maternal age and the number of detectable crossover events.
  • By contrast, in meiosis II cases we observed preferential pericentromeric exchanges covering the proximal 5.7 Mb region, with interaction between maternal age and the location of the crossover.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 1994 Sep;3(9):1521-8 [7833906.001]
  • [Cites] Hum Mol Genet. 1994 Aug;3(8):1365-71 [7987316.001]
  • [Cites] Genetics. 1995 Dec;141(4):1339-49 [8601478.001]
  • [Cites] Am J Hum Genet. 1996 Mar;58(3):628-33 [8644722.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4979-83 [8643515.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):374-6 [8944012.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):400-5 [8944019.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):406-14 [8944020.001]
  • [Cites] Hum Mol Genet. 1997 Sep;6(9):1391-9 [9285774.001]
  • [Cites] Am J Hum Genet. 2005 Jan;76(1):91-9 [15551222.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):756-60 [15951820.001]
  • [Cites] Cytogenet Genome Res. 2005;111(3-4):250-5 [16192701.001]
  • [Cites] Public Health Rep. 2007 Jan-Feb;122(1):62-72 [17236610.001]
  • [Cites] Am J Hum Genet. 2007 Mar;80(3):526-30 [17273974.001]
  • [Cites] Ment Retard Dev Disabil Res Rev. 2007;13(3):221-7 [17910090.001]
  • [Cites] PLoS Genet. 2008 Mar;4(3):e1000033 [18369452.001]
  • [Cites] Hum Mol Genet. 1996;5 Spec No:1495-504 [8875256.001]
  • [Cites] Chromosoma. 2000 Nov;109(7):435-8 [11151672.001]
  • [Cites] Mol Hum Reprod. 2001 Jan;7(1):49-55 [11134360.001]
  • [Cites] Science. 2004 Feb 27;303(5662):1367-70 [14752166.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):744-9 [15208629.001]
  • [Cites] Hum Genet. 1985;70(1):11-7 [3997148.001]
  • [Cites] Science. 1987 Aug 7;237(4815):652-4 [2955519.001]
  • [Cites] N Engl J Med. 1991 Mar 28;324(13):872-6 [1825697.001]
  • [Cites] Am J Hum Genet. 1991 Sep;49(3):608-20 [1831960.001]
  • [Cites] Am J Hum Genet. 1992 Mar;50(3):544-50 [1347192.001]
  • [Cites] Cytogenet Cell Genet. 1994;65(3):194-202 [8222760.001]
  • [Cites] Genetics. 1994 Jan;136(1):65-74 [8138177.001]
  • [Cites] Am J Hum Genet. 1995 Oct;57(4):867-74 [7573048.001]
  • (PMID = 19533770.001).
  • [ISSN] 1552-4833
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD038979-01; United States / NICHD NIH HHS / HD / R01 HD038979; United States / NHGRI NIH HHS / HG / HG002374-01; United States / NICHD NIH HHS / HD / HD038979-01; United States / NHGRI NIH HHS / HG / R01 HG002374; United States / NICHD NIH HHS / HD / R01 HD38979; United States / NHGRI NIH HHS / HG / R01 HG002374-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS135089; NLM/ PMC2732749
  •  go-up   go-down


50. Hall JE, Sullivan JP, Richardson GS: Brief wake episodes modulate sleep-inhibited luteinizing hormone secretion in the early follicular phase. J Clin Endocrinol Metab; 2005 Apr;90(4):2050-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the influence of sleep, sleep stage, and time of day on the dynamics of pulsatile LH secretion in the early follicular phase (EFP) of the menstrual cycle, 11 normal women underwent simultaneous polysomnographic monitoring of sleep and measurement of LH in frequent sampling studies during a 40-h protocol that consisted of one night of normal sleep and one night of sleep deprivation followed by an afternoon nap.
  • Wakefulness was more likely to be associated with an LH pulse than were stages I/II, III/IV (slow wave), or rapid eye movement sleep (P < 0.005).
  • [MeSH-minor] Adult. Electroencephalography. Female. Humans. Time Factors. Wakefulness / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671093.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-15080; United States / NCRR NIH HHS / RR / M01 RR01066; United States / NICHD NIH HHS / HD / U54 HD29164
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


51. Henry DE, Cheng YW, Shaffer BL, Kaimal AJ, Bianco K, Caughey AB: Perinatal outcomes in the setting of active phase arrest of labor. Obstet Gynecol; 2008 Nov;112(5):1109-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LEVEL OF EVIDENCE: II.

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2003 Oct;102(4):791-800 [14551010.001]
  • [Cites] Obstet Gynecol. 2000 Apr;95(4):589-95 [10725495.001]
  • [Cites] Obstet Gynecol. 2001 Oct;98(4):550-4 [11576566.001]
  • [Cites] Pediatrics. 2008 Apr;121(4):788-801 [18381544.001]
  • [Cites] Am J Obstet Gynecol. 1987 Apr;156(4):935-9 [3578404.001]
  • [Cites] Obstet Gynecol. 1993 May;81(5 ( Pt 1)):758-63 [8469468.001]
  • [Cites] Obstet Gynecol. 1999 Mar;93(3):323-8 [10074971.001]
  • (PMID = 18978113.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / 5T32 HD007162-27; United States / NICHD NIH HHS / HD / K12 HD001262; United States / NICHD NIH HHS / HD / L30 HD045176; United States / NICHD NIH HHS / HD / HD045176-02; United States / NICHD NIH HHS / HD / L30 HD045176-02; United States / NCRR NIH HHS / RR / TL1 RR024131-01; United States / NICHD NIH HHS / HD / HD01262; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NICHD NIH HHS / HD / T32 HD007162; United States / NICHD NIH HHS / HD / L30 HD045176-03; United States / NICHD NIH HHS / HD / HD045176-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS108536; NLM/ PMC2700839
  •  go-up   go-down


52. Nygaard I, Handa V, Brubaker L, Borello-France D, Wei J, Wells E, Weber AM, Pelvic Floor Disorders Network: Physical activity in women planning sacrocolpopexy. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jan;18(1):33-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activity frequencies did not generally differ by prolapse stage.
  • Prolapse stage was not associated with interference with household/yard work (p=0.28) or work outside home (p=0.89).
  • Although prolapse stage is associated with interference with recreation (p=0.02), this association is not consistently positive : stage II, 42%; stage III, 22%; and stage IV, 32%.
  • [MeSH-minor] Adult. Aged. Female. Gynecologic Surgical Procedures. Housekeeping. Humans. Middle Aged. Prolapse. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688397.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD41249; United States / NICHD NIH HHS / HD / U10 HD41248; United States / NICHD NIH HHS / HD / U10 HD41250; United States / NICHD NIH HHS / HD / U10 HD41261; United States / NICHD NIH HHS / HD / U10 HD41263; United States / NICHD NIH HHS / HD / U10 HD41267; United States / NICHD NIH HHS / HD / U10 HD41268; United States / NICHD NIH HHS / HD / U10 HD41269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


53. Trowbridge ER, Fultz NH, Patel DA, DeLancey JO, Fenner DE: Distribution of pelvic organ support measures in a population-based sample of middle-aged, community-dwelling African American and white women in southeastern Michigan. Am J Obstet Gynecol; 2008 May;198(5):548.e1-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The POP-Q stages were organized in the following manner: stage 0, 8.8%; stage I, 21.4%; stage II, 67.7%; stage III, 2.1%.

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2006 May;175(5):1769-72 [16600755.001]
  • [Cites] Arch Iran Med. 2006 Apr;9(2):124-8 [16649354.001]
  • [Cites] Am J Obstet Gynecol. 2000 Aug;183(2):277-85 [10942459.001]
  • [Cites] Am J Obstet Gynecol. 2002 Apr;186(4):712-6 [11967496.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):795-806 [15746674.001]
  • [Cites] Obstet Gynecol. 2004 Sep;104(3):489-97 [15339758.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Am J Obstet Gynecol. 1996 Dec;175(6):1467-70; discussion 1470-1 [8987926.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):299-305 [9988790.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jun;186(6):1160-6 [12066091.001]
  • (PMID = 18455530.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD041123-05; United States / NICHD NIH HHS / HD / R01 HD041123; United States / NICHD NIH HHS / HD / R01 HD 041123; United States / NICHD NIH HHS / HD / R01 HD041123-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS118140; NLM/ PMC2753829
  •  go-up   go-down


54. Buhimschi IA, Zambrano E, Pettker CM, Bahtiyar MO, Paidas M, Rosenberg VA, Thung S, Salafia CM, Buhimschi CS: Using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. Obstet Gynecol; 2008 Feb;111(2 Pt 1):403-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The prevalence of histologic chorioamnionitis was 64% (stage I 12%, stage II 16%, and stage III 37%).
  • Of the four biomarkers of the Mass Restricted score, calgranulin C had the strongest relationship with presence of stage III chorioamnionitis, independent of race, amniocentesis-to-delivery interval, and gestational age.
  • LEVEL OF EVIDENCE: II.

  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238979.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD047321-01; United States / NICHD NIH HHS / HD / R01 HD047321; United States / NICHD NIH HHS / HD / R01 HD047321-05; United States / NICHD NIH HHS / HD / R01 HD 047321-01; United States / NICHD NIH HHS / HD / R01 HD047321-03; United States / NICHD NIH HHS / HD / R01 HD047321-02; United States / NICHD NIH HHS / HD / R01 HD047321-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proteome
  •  go-up   go-down


55. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma; 2006 Apr;47(4):641-56
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.
  • Advanced-stage or relapsed/refractory Hodgkin's disease (HD) has a poor prognosis despite aggressive chemotherapy regimens and the use of high-dose therapy with autologous stem cell support.
  • Mitoxantrone, vinblastine and CCNU (lomustine) (MVC) combines the most effective chemotherapeutic agents of previous regimens for poor prognosis HD, and eliminates marginally active agents with unnecessary toxicities, such as bleomycin and dacarbazine.
  • Sixty-eight patients with HD (23 newly diagnosed and 45 with relapsed/refractory disease, one patient treated both de novo and years later in relapse) were treated with the MVC regimen (mitoxantrone 8 mg/m(2)/day i.v. days 1 - 3; vinblastine 8 m/m(2)/day days 1 and 22; and CCNU (lomustine) 100 mg/m(2) on day 1, repeated at 6 - 8 weeks) in a single-arm Phase II study.
  • MVC regimen for HD is highly active, for both de novo and relapsed/refractory disease, with high response rates and survival that compare favourably with the results obtained by high-dose therapy with stem-cell transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lomustine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Vinblastine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690523.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA14958; United States / NCI NIH HHS / CA / P30CA13330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


56. Ryali ME, Whittier WL: Bullous skin lesions in a patient undergoing chronic hemodialysis. Semin Dial; 2010 Jan-Feb;23(1):83-7
MedlinePlus Health Information. consumer health - Dialysis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reduced activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D) results in accumulation of photosensitive porphyrins; this ultimately leads to the skin fragility and blistering that is characteristic of this disease.
  • Less commonly, PCT has been documented in patients with end-stage renal disease.
  • The pathogenesis of PCT in long-term hemodialysis (HD) has been attributed to many factors, but the following mechanisms have been implicated: (i) decreased hepatic URO-D activity due to suppressive effects of iron and other hepatotoxins and (ii) poor porphyrin clearance by renal replacement therapies.
  • We report a case of PCT that developed in a patient on maintenance HD for 4 years.
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20331820.001).
  • [ISSN] 1525-139X
  • [Journal-full-title] Seminars in dialysis
  • [ISO-abbreviation] Semin Dial
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Soleymanian T, Raman S, Shannaq FN, Richardson R, Jassal SV, Bargman J, Oreopoulos DG: Survival and morbidity of HIV patients on hemodialysis and peritoneal dialysis: one center's experience and review of the literature. Int Urol Nephrol; 2006;38(2):331-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Total follow-up of HIV-infected PD and HD patients was 248.3 and 207 patient months, respectively.
  • There was no significant difference in hospitalization rate between HIV-infected PD and HD patients (1.01 and 1.39 admission/year, respectively, P = NS).
  • Survival of HIV-infected patients on PD at one, two and three years was 100, 83, and 50%, and for HD patients was 75, 33, and 33%, respectively.
  • HIV-infected patients on HD had more prevalent advanced HIV disease.
  • Two out of seven PD patients were on PD for more than five years and one of the HD patients was on that form of dialysis for more than nine years.
  • Median survival of patients with advanced (Stage IV) AIDS (both HD and PD) was 15.1 months (range 1.6-17.3) while this value for non-advanced (Stage II, III) patients was 61.2 months (range 6.8-116.6).
  • Survival is worse in patients with advanced HIV disease.
  • [MeSH-minor] Adult. Comorbidity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Middle Aged. Peritoneal Dialysis / adverse effects. Peritoneal Dialysis / mortality. Retrospective Studies. Survival Analysis


58. Howard K, Salkeld G, White S, McDonald S, Chadban S, Craig JC, Cass A: The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology (Carlton); 2009 Feb;14(1):123-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A multiple cohort Markov model was used to assess costs and health outcomes of RRT for new end-stage kidney disease (ESKD) patients in Australia for 2005-2010, using a health-care funder perspective.
  • Two proposed changes were modelled: (i) increasing kidney transplants by between 10% and 50% by 2010; and (ii) increasing home haemodialysis (HD) and peritoneal dialysis (PD) to the highest rates observed among Australian centres.
  • Switching new patients from hospital HD to (i) home HD saves $A46.6 million by 2010; or (ii) PD saves $A122.1 million.
  • [MeSH-minor] Adult. Aged. Cost-Benefit Analysis. Humans. Middle Aged. Quality-Adjusted Life Years. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207859.001).
  • [ISSN] 1440-1797
  • [Journal-full-title] Nephrology (Carlton, Vic.)
  • [ISO-abbreviation] Nephrology (Carlton)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


59. Klingele CJ, Bharucha AE, Fletcher JG, Gebhart JB, Riederer SG, Zinsmeister AR: Pelvic organ prolapse in defecatory disorders. Obstet Gynecol; 2005 Aug;106(2):315-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Fifty-five percent of controls, 42% of those with obstructed defecation, and 29% of those with fecal incontinence had stage II or greater prolapse by clinical examination.
  • Even after controlling for a higher prevalence of obstetric risk factors and hysterectomy, fecal incontinence was associated with a lower risk of stage II or greater pelvic organ prolapse (odds ratio for fecal incontinence in > or = stage II pelvic organ prolapse relative to stage 0 pelvic organ prolapse = 0.1, 95% confidence interval 0.01-0.53).
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Pregnancy. Prevalence. Risk Factors

  • MedlinePlus Health Information. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055581.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD 41129; United States / NICHD NIH HHS / HD / R01 HD 38666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


60. Balasubramaniyan N, Shahid M, Suchy FJ, Ananthanarayanan M: Multiple mechanisms of ontogenic regulation of nuclear receptors during rat liver development. Am J Physiol Gastrointest Liver Physiol; 2005 Feb;288(2):G251-60
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that transporters involved in bile formation are developmentally regulated and are poorly developed during the fetal stage, but their expression reached gradual maturity during the postnatal period.
  • To define the molecular mechanisms underlying this regulation and the role that class II NRs and associated members [liver receptor homolog-1 (LRH-1) and short heterodimer partner (SHP)] play, we have analyzed the ontogeny of NR expression during liver development.
  • Real-time PCR analysis of hepatic NR expression from fetal day 17 through adult revealed that steady-state mRNA levels for all NRs were very low during the embryonic period.
  • However, mRNA levels peaked close to that of adult rats (>6 wk-old rats) by 4 wk of age for farnesoid X receptor (FXR), pregnane X receptor (PXR), liver X receptor-alpha (LXRalpha), peroxisome proliferator-activated receptor-alpha (PPARalpha), retinoid acid receptor-alpha (RARalpha), LRH-1, and SHP, whereas RXRalpha mRNA lagged behind.
  • FXR, PXR, LXRalpha, RARalpha, and PPARalpha functional activity in liver nuclear extracts assayed by gel EMSA demonstrated that the activity attained adult levels by 4 wk of age, exhibiting a strict correlation with mRNA levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388488.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-20632
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear
  •  go-up   go-down


61. Montinaro V, Iaffaldano GP, Granata S, Porcelli P, Todarello O, Schena FP, Pertosa G: Emotional symptoms, quality of life and cytokine profile in hemodialysis patients. Clin Nephrol; 2010 Jan;73(1):36-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mental disorders are frequent in hemodialysis (HD) patients.
  • The aim of this study was to assess the psychological alterations and QOL in HD patients, and to correlate them with pattern of cytokine production.
  • METHODS: 30 HD patients and 20 subjects with CKD Stage I-II K-DOQI.
  • 2) Kidney Disease Quality of Life (KDQOL) modified, including a cognitive function subscale (KDQOL-CF).
  • Whole blood samples collected at beginning of HD session were diluted with RPMI/heparin and incubated for 24 h in presence of lipopolysaccharide (LPS).
  • RESULTS: A depressive mood was more frequent in HD patients (50%) than controls (20%, p < 0.0001).
  • No difference for anxiety (HD = 43%, controls = 45%) was observed.
  • QOL score was significantly lower in HD than controls (p = 0.006) and correlated inversely with HADS total, HADS-A and HADS-D (p < 0.0001).
  • Cytokine production was significantly higher in HD patients than controls (IL-1beta p = 0.05; IL-6 p = 0.010; TNF-alpha p < 0.0001; IL-10, p = 0.0019).
  • HD patients with the HADS-A positive for anxiety showed higher IL-6 production (p = 0.026), while IL-1beta levels were not associated with symptoms of depression.
  • CONCLUSIONS: HD patients have symptoms of depression and anxiety that negatively affect QOL.
  • [MeSH-minor] Adult. Aged. Anxiety / blood. Anxiety / psychology. Depression / blood. Depression / psychology. Emotions. Female. Humans. Inflammation / blood. Inflammation / psychology. Male. Middle Aged. Patient Selection. Psychiatric Status Rating Scales. Severity of Illness Index. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040350.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


62. Karg E, Papp F, Tassi N, Janáky T, Wittmann G, Túri S: Enhanced methylglyoxal formation in the erythrocytes of hemodialyzed patients. Metabolism; 2009 Jul;58(7):976-82
Hazardous Substances Data Bank. METHYL GLYOXAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, the present study was aimed to investigate the formation and degradation of MG in the erythrocytes of hemodialyzed (HD) patients with end-stage renal disease.
  • In 22 nondiabetic patients on long-term HD, erythrocyte MG and d-lactate levels, glyoxalase activities, and whole blood reduced glutathione content were determined.
  • The erythrocyte MG levels were elevated (P < .001) in the HD patients.
  • The blood reduced glutathione content and glyoxalase I activity were similar to the control levels, but the glyoxalase II activity was significantly (P < .005) increased.
  • In the normoglycemic in vitro model, production of both MG (P < .001) and d-lactate (P < .002) was significantly enhanced in the HD erythrocytes relative to the controls.
  • The present study demonstrated an increased formation of MG in the erythrocytes of HD patients.
  • The alterations and imbalance of these metabolic processes may contribute to the carbonyl overload and stress in the HD patients.
  • [MeSH-minor] Adult. Case-Control Studies. Female. Glutathione / blood. Humans. Lactic Acid / blood. Lactoylglutathione Lyase / blood. Male. Middle Aged. Tandem Mass Spectrometry. Thiolester Hydrolases / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394056.001).
  • [ISSN] 1532-8600
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid; 722KLD7415 / Pyruvaldehyde; EC 3.1.2.- / Thiolester Hydrolases; EC 3.1.2.6 / hydroxyacylglutathione hydrolase; EC 4.4.1.5 / Lactoylglutathione Lyase; GAN16C9B8O / Glutathione
  •  go-up   go-down


63. Salem HA, Eissa LA, Rabbie AM, El-Helw LM, El-Gayar AM: Evaluation of some biochemical markers as prognostic factors in malignant lymphomas. Pak J Pharm Sci; 2006 Jul;19(3):219-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage.
  • For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital.
  • Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV.
  • RESULTS: 1-Pre-treatment levels of GAGs, sp55TNF-R and sL-selectin increased significantly in both HD and NHL before treatment as compared to control.
  • Pre-treatment sp55TNF-R levels in both diseases and sL-selectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sL-selectin in NHL patients had a limited value in such prediction.
  • 2- In contrast to sp55TNF-R and sL-selectin, post-treatment GAG levels are thought to be a good sign of remission in both HD and NHL.
  • 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • CONCLUSION: Pre-treatment sp55TNF-R levels in both HD & NHL and sL-selectin (only in HD patients) could be used as prognostic factor with respect to predicting treatment outcome.
  • Serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • [MeSH-major] Biomarkers, Tumor. Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Blood Cell Count. Blood Sedimentation. Female. Glycosaminoglycans / metabolism. Humans. Kidney Function Tests. L-Lactate Dehydrogenase / metabolism. L-Selectin / metabolism. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Tumor Necrosis Factor, Type I / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935830.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycosaminoglycans; 0 / Receptors, Tumor Necrosis Factor, Type I; 126880-86-2 / L-Selectin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


64. Mann JS, Lowther KM, Mehlmann LM: Reorganization of the endoplasmic reticulum and development of Ca2+ release mechanisms during meiotic maturation of human oocytes. Biol Reprod; 2010 Oct;83(4):578-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immature, germinal vesicle (GV)-stage oocytes had a fine network of ER throughout the cortex and interior, whereas the ER in the in vivo-matured, metaphase II oocytes was organized in large (diameter, ∼2-3 μm) accumulations throughout the cortex and interior.
  • In vivo-matured oocytes contained approximately 1.5-fold the amount of IP(3) receptor protein and released significantly more Ca(2+) in response to IP(3) compared with GV-stage oocytes; however, oocytes matured in vitro did not contain more IP(3) receptor protein or release more Ca(2+) in response to IP(3) compared with GV-stage oocytes.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod. 1992 Aug;7(7):999-1003 [1430145.001]
  • [Cites] Science. 1992 Jul 10;257(5067):251-5 [1321497.001]
  • [Cites] Dev Biol. 1993 Mar;156(1):69-79 [8383620.001]
  • [Cites] Methods Cell Biol. 1993;38:211-20 [8246782.001]
  • [Cites] Hum Reprod. 1993 Dec;8(12):2174-9 [8150920.001]
  • [Cites] Dev Biol. 1994 Aug;164(2):579-87 [8045353.001]
  • [Cites] Development. 1994 Jul;120(7):1851-9 [7924992.001]
  • [Cites] Development. 1994 Dec;120(12):3507-17 [7821218.001]
  • [Cites] Biol Reprod. 1994 Dec;51(6):1088-98 [7888488.001]
  • [Cites] Dev Biol. 1995 Aug;170(2):594-606 [7649386.001]
  • [Cites] Dev Biol. 1995 Aug;170(2):607-15 [7649387.001]
  • [Cites] Development. 1995 Oct;121(10):3259-66 [7588060.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):489-98 [8954721.001]
  • [Cites] Mol Hum Reprod. 1997 Nov;3(11):965-73 [9433922.001]
  • [Cites] Dev Biol. 1998 Nov 1;203(1):221-32 [9806786.001]
  • [Cites] Dev Biol. 1998 Nov 15;203(2):305-22 [9808782.001]
  • [Cites] Mol Hum Reprod. 1999 May;5(5):441-51 [10338367.001]
  • [Cites] Dev Biol. 1999 Jul 15;211(2):157-76 [10395780.001]
  • [Cites] Dev Biol. 1999 Oct 15;214(2):399-411 [10525343.001]
  • [Cites] Hum Reprod. 2005 May;20(5):1349-58 [15695316.001]
  • [Cites] Cloning Stem Cells. 2005;7(4):306-20 [16390266.001]
  • [Cites] Semin Cell Dev Biol. 2006 Apr;17(2):233-43 [16549376.001]
  • [Cites] Dev Biol. 2007 May 1;305(1):133-44 [17368610.001]
  • [Cites] Fertil Steril. 2008 Jan;89(1):84-91 [17462639.001]
  • [Cites] Dev Biol. 2008 Mar 15;315(2):257-79 [18255053.001]
  • [Cites] Reprod Biol. 2008 Mar;8(1):3-22 [18432304.001]
  • [Cites] Dev Biol. 2008 Aug 15;320(2):402-13 [18621368.001]
  • [Cites] Biol Reprod. 2009 Jul;81(1):147-54 [19299317.001]
  • [Cites] Cell Calcium. 2009 Jul;46(1):56-64 [19482353.001]
  • [Cites] Anim Sci J. 2010 Feb;81(1):34-41 [20163670.001]
  • [Cites] Semin Cell Dev Biol. 2006 Apr;17(2):264-73 [16730199.001]
  • [Cites] Development. 2006 Nov;133(21):4355-65 [17038520.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1277-91 [16996508.001]
  • [Cites] Dev Biol. 1999 Nov 15;215(2):431-42 [10545249.001]
  • [Cites] Mol Biol Cell. 2001 Apr;12(4):1103-16 [11294910.001]
  • [Cites] Dev Biol. 2002 May 15;245(2):237-54 [11977978.001]
  • [Cites] Mol Hum Reprod. 2002 Oct;8(10):912-8 [12356940.001]
  • [Cites] Dev Biol. 2002 Oct 15;250(2):280-91 [12376103.001]
  • [Cites] Dev Biol. 2003 Dec 1;264(1):50-63 [14623231.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Jun;16(3):211-9 [15129050.001]
  • [Cites] Dev Biol. 1977 May;57(1):56-74 [863112.001]
  • [Cites] Dev Biol. 1985 Feb;107(2):382-94 [4038667.001]
  • [Cites] Dev Biol. 1988 Nov;130(1):184-97 [3141231.001]
  • [Cites] J Cell Biol. 1990 Apr;110(4):1103-10 [2324195.001]
  • [Cites] Dev Biol. 1990 Aug;140(2):300-6 [2373255.001]
  • [Cites] Mol Reprod Dev. 1991 Feb;28(2):183-8 [2007032.001]
  • [Cites] J Physiol. 1992 Sep;455:623-40 [1484365.001]
  • (PMID = 20610804.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD056366; United States / NICHD NIH HHS / HD / HD056366
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inositol 1,4,5-Trisphosphate Receptors; 85166-31-0 / Inositol 1,4,5-Trisphosphate; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2957155
  •  go-up   go-down


65. Asmis LM, Segal JB, Plantinga LC, Fink NE, Kerman JS, Kickler TS, Coresh J, Gardner LB: Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost; 2008 Sep;100(3):498-504
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were (i) to determine the prevalence of HIA in patients treated by dialysis, (ii) to determine the prevalence of thrombocytopenia and heparin-induced thrombocytopenia (HIT), and (iii) to test whether HIA are associated with adverse outcomes.
  • Sera from 740 patients treated by hemodialysis (HD, n=596) and peritoneal dialysis (PD, n=144) were tested for HIA (IgG, IgA or IgM) by masked investigators at approximately six months after enrolment in the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study.
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoglobulin A / analysis. Immunoglobulin G / analysis. Immunoglobulin M / analysis. Male. Middle Aged. Peritoneal Dialysis. Platelet Count. Renal Dialysis. Risk

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766268.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR000052; United States / NIDDK NIH HHS / DK / R01-DK-59616; United States / NHLBI NIH HHS / HL / R01-HL-62985
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 9005-49-6 / Heparin
  •  go-up   go-down


66. Matos JM, Grützmann R, Agaram NP, Saeger HD, Kumar HR, Lillemoe KD, Schmidt CM: Solid pseudopapillary neoplasms of the pancreas: a multi-institutional study of 21 patients. J Surg Res; 2009 Nov;157(1):e137-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AJCC stages were stage I (18), stage II (1), stage III (2), and stage IV (0).
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Surg Res. 2010 Nov;164(1):74
  • (PMID = 19818965.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


67. Lee NP, Cheng CY: Protein kinases and adherens junction dynamics in the seminiferous epithelium of the rat testis. J Cell Physiol; 2005 Feb;202(2):344-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both Sertoli and germ cells were shown to express c-Src, Csk, and CK2 with a relative Sertoli:germ cell ratio of approximately 1:1, suggesting both cell types contributed equally to the pool of these kinases in the epithelium. c-Src and Csk were shown to be stage-specific proteins during the epithelial cycle, being highest at stages VII-VIII.
  • When adult rats were treated with 1-(2,4-dichlorobenzyl)-indazole-3-carbohydrazide (AF-2364), a compound known to induce germ cell loss from the seminiferous epithelium, in particular elongating/elongate and round spermatids, by disrupting Sertoli-germ cell AJs, an induction of c-Src and Csk, but not CK2, was detected.
  • Administration of PP1, a c-Src inhibitor, into adult rats via the jugular vein could induce the loss of spermatocytes and round spermatids, but not elongating/elongate spermatids, from the seminiferous epithelium.
  • [MeSH-minor] Animals. Cadherins / metabolism. Casein Kinase II / metabolism. Cell Adhesion / drug effects. Cell Cycle. Cells, Cultured. Coculture Techniques. Cytoskeletal Proteins / metabolism. Hydrazines / pharmacology. Indazoles / pharmacology. Male. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins pp60(c-src) / metabolism. Pyrazoles / pharmacology. Pyrimidines / pharmacology. Rats. Rats, Sprague-Dawley. Sertoli Cells / metabolism. Spermatozoa / metabolism. Tissue Distribution. Trans-Activators / metabolism. beta Catenin. src-Family Kinases

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc
  • (PMID = 15389520.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD45908; United States / NICHD NIH HHS / HD / U54 HD29990
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-(2,4-dichlorobenzyl)indazole-3-carbohydrazide; 0 / 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; 0 / Cadherins; 0 / Ctnnb1 protein, rat; 0 / Cytoskeletal Proteins; 0 / Fath protein, mouse; 0 / Fath protein, rat; 0 / Hydrazines; 0 / Indazoles; 0 / Pyrazoles; 0 / Pyrimidines; 0 / Trans-Activators; 0 / beta Catenin; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Matk protein, mouse; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / CSK tyrosine-protein kinase; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src); EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.1 / Casein Kinase II
  •  go-up   go-down


68. Sun S, Wong EW, Li MW, Lee WM, Cheng CY: 14-3-3 and its binding partners are regulators of protein-protein interactions during spermatogenesis. J Endocrinol; 2009 Sep;202(3):327-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During spermatogenesis, spermiation takes place at the adluminal edge of the seminiferous epithelium at stage VIII of the epithelial cycle during which fully developed spermatids (i.e. spermatozoa) detach from the epithelium in adult rat testes.
  • At stage XIV of the epithelial cycle, Pachytene spermatocytes (diploid, 2n) differentiate into diplotene spermatocytes (tetraploid, 4n) in the apical compartment of the epithelium, which begin meiosis I to be followed by meiosis II to form spermatids (haploid, 1n) at stage XIV of the epithelial cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2005 Aug;204(2):470-83 [15690393.001]
  • [Cites] Mol Cell Proteomics. 2005 Jun;4(6):785-95 [15778465.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25029-47 [15870075.001]
  • [Cites] Sci STKE. 2005 Aug 9;2005(296):re10 [16091624.001]
  • [Cites] IUBMB Life. 2005 Sep;57(9):623-9 [16203681.001]
  • [Cites] J Biol Chem. 2006 Jun 2;281(22):15475-84 [16595684.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):162-72 [16678438.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17286-303 [16608848.001]
  • [Cites] Curr Pharm Biotechnol. 2006 Jun;7(3):217-23 [16789906.001]
  • [Cites] Trends Cell Biol. 2006 Jul;16(7):370-5 [16769213.001]
  • [Cites] Biol Chem. 2006 Sep;387(9):1227-36 [16972791.001]
  • [Cites] J Cell Sci. 2006 Oct 1;119(Pt 19):4059-70 [16968750.001]
  • [Cites] J Endocrinol. 2006 Sep;190(3):759-70 [17003277.001]
  • [Cites] Oncogene. 2008 Feb 21;27(9):1315-9 [17704798.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):614-30 [18005931.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):692-708 [18068662.001]
  • [Cites] Front Biosci. 2008;13:6520-36 [18508678.001]
  • [Cites] Pharmacol Rev. 2008 Jun;60(2):146-80 [18483144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9657-62 [18621709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10402-7 [18641122.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5435-43 [10553069.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:617-47 [10836149.001]
  • [Cites] Exp Cell Res. 2000 May 25;257(1):172-9 [10854065.001]
  • [Cites] J Mol Evol. 2000 Nov;51(5):446-58 [11080367.001]
  • [Cites] Science. 2001 Jan 12;291(5502):316-9 [11209084.001]
  • [Cites] Cell. 2001 Apr 20;105(2):257-67 [11336675.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(18):6312-21 [11509672.001]
  • [Cites] Plant Physiol. 2001 Sep;127(1):142-9 [11553742.001]
  • [Cites] J Androl. 2001 Nov-Dec;22(6):1030-52 [11700851.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):53-7 [11911880.001]
  • [Cites] Physiol Rev. 2002 Oct;82(4):825-74 [12270945.001]
  • [Cites] Genes Cells. 2002 Nov;7(11):1161-71 [12390250.001]
  • [Cites] J Physiol. 2002 Nov 15;545(Pt 1):13-26 [12433946.001]
  • [Cites] Cell. 2002 Nov 15;111(4):577-88 [12437930.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 17;300(3):679-85 [12507503.001]
  • [Cites] Endocrinology. 2003 May;144(5):2141-63 [12697723.001]
  • [Cites] Curr Biol. 2003 Apr 15;13(8):638-46 [12699619.001]
  • [Cites] Trends Cell Biol. 2003 Jun;13(6):295-300 [12791295.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1330-4 [12906794.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36323-7 [12865427.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5734-45 [14592972.001]
  • [Cites] Curr Biol. 2003 Dec 2;13(23):2082-90 [14653998.001]
  • [Cites] Cell. 2004 Jan 23;116(2):153-66 [14744428.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12804-11 [14676191.001]
  • [Cites] Curr Biol. 2004 Apr 20;14(8):736-41 [15084291.001]
  • [Cites] J Cell Sci. 2004 Apr 15;117(Pt 10):1875-84 [15090593.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):329-42 [15167810.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):392-404 [15056568.001]
  • [Cites] Sci STKE. 2004 Jul 20;2004(242):re10 [15266103.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32046-54 [15161933.001]
  • [Cites] Curr Biol. 2004 Aug 24;14(16):1425-35 [15324659.001]
  • [Cites] Curr Biol. 2004 Aug 24;14(16):1436-50 [15324660.001]
  • [Cites] Endocr Rev. 2004 Oct;25(5):747-806 [15466940.001]
  • [Cites] J Neurochem. 1982 May;38(5):1475-82 [7062063.001]
  • [Cites] Nature. 1995 Jul 13;376(6536):188-91 [7603573.001]
  • [Cites] Nature. 1995 Jul 13;376(6536):191-4 [7603574.001]
  • [Cites] FEBS Lett. 1995 Jul 10;368(1):55-8 [7615088.001]
  • [Cites] J Mol Evol. 1996 Oct;43(4):384-98 [8798343.001]
  • [Cites] Curr Biol. 1996 Sep 1;6(9):1104-13 [8805370.001]
  • [Cites] Mol Reprod Dev. 1997 Aug;47(4):370-9 [9211421.001]
  • [Cites] Science. 1997 Sep 5;277(5331):1501-5 [9278512.001]
  • [Cites] Cell. 1997 Dec 26;91(7):961-71 [9428519.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16305-10 [9632691.001]
  • [Cites] Plant Physiol. 1998 Nov;118(3):1041-8 [9808749.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5762-8 [10026197.001]
  • [Cites] Biochemistry. 1999 Apr 20;38(16):5216-21 [10213629.001]
  • [Cites] J Androl. 1999 Mar-Apr;20(2):198-213 [10232655.001]
  • [Cites] Genes Dev. 1999 May 1;13(9):1067-72 [10323858.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):153-66 [10488331.001]
  • [Cites] J Cell Physiol. 2005 Feb;202(2):344-60 [15389520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1222-7 [15644438.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1192-204 [15591141.001]
  • (PMID = 19366886.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD056034-01A2; United States / NICHD NIH HHS / HD / HD029990-170005; United States / NICHD NIH HHS / HD / U54 HD029990-170005; United States / NICHD NIH HHS / HD / R03 HD051512; United States / NICHD NIH HHS / HD / HD056034-01A2; United States / NICHD NIH HHS / HD / HD051512-02; United States / NICHD NIH HHS / HD / U54 HD029990; United States / NICHD NIH HHS / HD / R01 HD056034; United States / NICHD NIH HHS / HD / R03 HD051512-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 14-3-3 Proteins
  • [Number-of-references] 75
  • [Other-IDs] NLM/ NIHMS164091; NLM/ PMC2804912
  •  go-up   go-down


69. Saxena AK, Panhotra BR: The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study. J Nephrol; 2005 Nov-Dec;18(6):755-63
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Reduction in the rates of major complications such as infection and thrombosis that limit the lifespan of hemodialysis (HD) catheters could conceivably lead to improved survival of "temporary" non-tunneled HD catheters (NTCs).
  • METHODS: This prospective study included 208 (109 males and 99 females) end-stage renal disease (ESRD) patients of diverse etiology enrolled for long-term HD from July 2002 to June 2003 at our tertiary care hospital.
  • Those patients requiring NTC insertion for the maintenance or commencement of HD were eligible for the study.
  • RESULTS: An overall relative risk reduction (RRR) of 56.5% for catheter thrombosis and separately for all types of NTCs (femoral (FC) - 52.7%, subclavian (SC) - 55.9%, and internal jugular (IJC) - 53.7%), were observed in group II having a cefotaxime-heparin lock solution.
  • A lower CRBSI incidence (1.65 vs. 3.13/1000 catheter days) compared with group I, leading to a RRR of 50.5% was also recorded in group II.
  • Significantly higher percentage catheter survival rates at 7, 14 and at 28 days for FC and at 14, 28 and 56 days for SC and IJC were observed among patients in group II in comparison to group I.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Anticoagulants / therapeutic use. Case-Control Studies. Catheters, Indwelling / adverse effects. Confidence Intervals. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Prospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358235.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticoagulants; 9005-49-6 / Heparin; N2GI8B1GK7 / Cefotaxime
  •  go-up   go-down


70. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS: A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer; 2008 Oct 1;113(7):1632-40
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-eight patients with treatment-naive American Joint Committee on Cancer stage IV melanoma (8 patients with M1a disease, 6 patients with M1b disease, and 24 patients with M1c disease) were enrolled.
  • Responses were observed in patients with M1a disease and in patients with M1c disease.
  • Sixteen patients had stable disease (15 patients progressed).
  • CONCLUSIONS: The current results indicated that it is safe to administer HD IL-2 sequentially with temozolomide and that this combination has lower toxicity than previously used concurrent biochemotherapy regimens.
  • However, The ORR and the durability of responses with this combination did not exceed those of single-agent HD IL-2.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer. 2013 Feb 15;119(4):924
  • (PMID = 18720480.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


71. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol; 2006 Sep 1;24(25):4116-22
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
  • PURPOSE: To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD).
  • PATIENTS AND METHODS: We developed a decision-analytic model to evaluate follow-up strategies for two hypothetical cohorts of 25-year-old patients with stage I-II or stage III-IV HD, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine-based chemotherapy with or without radiation therapy, respectively.
  • With adjustments for quality of life, we found a decrement in quality-adjusted life expectancy for early-stage patients followed with CT compared with non-CT modalities.
  • For advanced-stage patients, annual CT for 5 years is associated with a very small quality-adjusted survival gain over non-CT follow-up with an incremental cost-effectiveness ratio of 9,042,300 dollars/QALY.
  • CONCLUSION: Our analysis suggests that routine CT should not be used in the surveillance of asymptomatic patients in CR after treatment for HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decision Support Techniques. Hodgkin Disease / economics. Hodgkin Disease / radiography. Population Surveillance / methods. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Life Expectancy. Markov Chains. Neoplasm Staging. Predictive Value of Tests. Quality-Adjusted Life Years. Sensitivity and Specificity. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943528.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R25 CA57711-11
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


72. Kepka L, Suit HD, Goldberg SI, Rosenberg AE, Gebhardt MC, Hornicek FJ, Delaney TF: Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol; 2005 Oct 1;92(1):39-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor characteristics: location, lower extremity (63%), upper extremity (27%), other (10%); median tumor size, 5 cm; grade-G1 (19%), G2 (49%), G3 (32%); AJCC stage (2002)-I (19%), II (54%), III (27%).
  • Depth in the relation to the fascia, tumor size, and AJCC stage significantly influenced local recurrence- and distant metastasis-free survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180232.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Sanabria M, Muñoz J, Trillos C, Hernández G, Latorre C, Díaz CS, Murad S, Rodríguez K, Rivera A, Amador A, Ardila F, Caicedo A, Camargo D, Díaz A, González J, Leguizamón H, Lopera P, Marín L, Nieto I, Vargas E: Dialysis outcomes in Colombia (DOC) study: a comparison of patient survival on peritoneal dialysis vs hemodialysis in Colombia. Kidney Int Suppl; 2008 Apr;(108):S165-72
Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of the Dialysis Outcomes in Colombia (DOC) study was to compare the survival of patients on hemodialysis (HD) vs peritoneal dialysis (PD) in a network of renal units in Colombia.
  • There were 1094 eligible patients in total and 923 were actually enrolled: 47.3% started HD therapy and 52.7% started PD therapy.
  • Also, there were differences in the median survival time between groups: 27.2 months for PD vs 23.1 months for HD (P=0.001) by the intention-to-treat approach; and 24.5 months for PD vs 16.7 months for HD (P<0.001) by the as-treated approach.
  • When performing univariate Cox analyses using the intention-to-treat approach, associations were with age > or =65 years (hazard ratio (HR)=2.21; confidence interval (CI) 95% (1.77-2.755); P<0.001); history of cardiovascular disease (HR=1.96; CI 95% (1.58-2.90); P<0.001); diabetes (HR=2.34; CI 95% (1.88-2.90); P<0.001); and SGA (mild or moderate-severe malnutrition) (HR=1.47; CI 95% (1.17-1.79); P=0.001); but no association was found with gender (HR=1.03, CI 95% 0.83-1.27; P=0.786).
  • Similarly, the multivariate Cox model was run with the variables that had shown association in previous analyses, and it was found that the variables explaining the survival of patients with end-stage renal disease in our study were age, SGA, Charlson Comorbidity Index 5 and above, diabetes, healthcare regimes I and II, and socioeconomic level 2.
  • The results of Cox proportional risk model in both the as-treated and intention-to-treat analyses showed that there were no statistically significant differences in survival of PD and HD patients: intention-to-treat HD/PD (HR 1.127; CI 95%: 0.855-1.484) and as-treated HD/PD (HR 1.231; CI 95%: 0.976-1.553).
  • In this historical cohort of incident patients, there was a trend, although not statistically significant, for a higher (12.7%) adjusted mortality risk associated with HD when compared to PD, even though the PD patients were poorer, were more likely to be diabetic, and had higher co-morbidity scores than the HD patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colombia. Diabetes Complications / complications. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Phosphorus / blood. Proportional Hazards Models. Socioeconomic Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379541.001).
  • [ISSN] 0098-6577
  • [Journal-full-title] Kidney international. Supplement
  • [ISO-abbreviation] Kidney Int. Suppl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 27YLU75U4W / Phosphorus
  •  go-up   go-down


74. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


75. Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS: Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab; 2008 May;93(5):1662-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We performed a case control study of PCOS children (n = 32) compared with children from control women (n = 38) for reproductive and metabolic abnormalities, stratifying results by three Tanner stage groupings.
  • Urine testosterone levels were significantly elevated in Tanner II-III PCOS boys compared with controls (P = 0.007).
  • We validated the correlation between salivary and serum levels of insulin (insulin areas under the curve) in an adult population [n =30, Pearson correlation coefficient (r) = 0.67; P < 0.0001], which also replicated in the children (2-h insulin r = 0.57; P = 0.0004).

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod Update. 2006 Nov-Dec;12(6):673-83 [16891296.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Oct;91(10):4112-7 [16868051.001]
  • [Cites] N Engl J Med. 2007 Feb 8;356(6):551-66 [17287476.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):787-96 [17179197.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2739-43 [17488788.001]
  • [Cites] Metabolism. 2008 Jan;57(1):84-9 [18078863.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):172-8 [7829608.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2136-41 [15644405.001]
  • [Cites] Hum Reprod. 2005 Aug;20(8):2122-6 [15802312.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4797-802 [15899949.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):492-7 [16249280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7030-5 [16632599.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1714-22 [16492701.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):430-6 [17118995.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1021-5 [10720033.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2122-5 [11000114.001]
  • [Cites] Am J Med. 2001 Dec 1;111(8):607-13 [11755503.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2128-33 [11994352.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2134-8 [11994353.001]
  • [Cites] Fertil Steril. 2002 Sep;78(3):569-76 [12215335.001]
  • [Cites] Fertil Steril. 2004 Jan;81(1):19-25 [14711538.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2622-31 [15181033.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2494-7 [15477412.001]
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Contraception. 1974 Dec;10(6):599-605 [4448070.001]
  • [Cites] J Clin Endocrinol Metab. 1975 May;40(5):783-89 [1173241.001]
  • [Cites] J Clin Invest. 1976 May;57(5):1320-9 [770505.001]
  • [Cites] Clin Chem. 1981 Nov;27(11):1892-5 [6794948.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Lancet. 1985 Dec 21-28;2(8469-70):1375-9 [2867389.001]
  • [Cites] Diabetologia. 1986 Oct;29(10):695-8 [3542670.001]
  • [Cites] Public Health Rep. 1988 Mar-Apr;103(2):143-7 [3128829.001]
  • [Cites] Diabetes Care. 1988 Jun;11(6):489-94 [3042316.001]
  • [Cites] Am J Clin Nutr. 1991 Dec;54(6):1005-10 [1957814.001]
  • [Cites] Ultrasound Med Biol. 1991;17(6):589-93 [1962361.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1353-6 [8636332.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):942-7 [8772555.001]
  • [Cites] Pediatrics. 1996 Oct;98(4 Pt 1):649-58 [8885941.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1131-5 [9343501.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14956-60 [9843997.001]
  • [Cites] Ann Epidemiol. 2006 Jun;16(6):429-31 [16280248.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):3105-9 [16720659.001]
  • [CommentIn] J Clin Endocrinol Metab. 2008 May;93(5):1576-8 [18463351.001]
  • (PMID = 18270257.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR 016499; United States / NCRR NIH HHS / RR / M01 RR010732; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NICHD NIH HHS / HD / U54 HD 034449; United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / U54 HD034449; United States / NICHD NIH HHS / HD / K24 HD 01476; United States / NCRR NIH HHS / RR / M01 RR 10732
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadotropins; 0 / Insulin; 0 / Lipids
  • [Other-IDs] NLM/ PMC2386683
  •  go-up   go-down


76. Lin FJ, Chen X, Qin J, Hong YK, Tsai MJ, Tsai SY: Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel development. J Clin Invest; 2010 May;120(5):1694-707
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conditional ablation of COUP-TFII at an early embryonic stage resulted in failed formation of pre-lymphatic ECs (pre-LECs) and lymphatic vessels.
  • COUP-TFII deficiency at a late developmental stage resulted in loss of LEC identity, gain of blood EC fate, and impaired lymphatic vessel sprouting. siRNA-mediated downregulation of COUP-TFII in cultured primary human LECs demonstrated that the maintenance of lymphatic identity and VEGF-C-induced lymphangiogenic activity, including cell proliferation and migration, are COUP-TFII-dependent and cell-autonomous processes.
  • In addition, COUP-TFII inactivation in a mammary gland mouse tumor model resulted in inhibition of tumor lymphangiogenesis, suggesting that COUP-TFII also regulates neo-lymphangiogenesis in the adult.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Jun;25(2):153-9 [10835628.001]
  • [Cites] Nature. 2005 May 5;435(7038):98-104 [15875024.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4649-56 [15705793.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4642-8 [15746084.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6901-9 [16061674.001]
  • [Cites] J Clin Invest. 2005 Sep;115(9):2382-92 [16100571.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3484-93 [16284652.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):946-53 [16355212.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2650-7 [16510584.001]
  • [Cites] Nat Med. 2006 Jun;12(6):711-6 [16732279.001]
  • [Cites] FASEB J. 2006 Jul;20(9):1462-72 [16816121.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1243-50 [16621967.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):593-9 [17234768.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 [17522591.001]
  • [Cites] Genes Dev. 2007 Oct 1;21(19):2422-32 [17908929.001]
  • [Cites] Genesis. 2007 Dec;45(12):768-75 [18064676.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):40-50 [18097475.001]
  • [Cites] Annu Rev Pathol. 2008;3:367-97 [18039141.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):331-42 [18394556.001]
  • [Cites] Lymphat Res Biol. 2008;6(2):69-76 [18564921.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5459-65 [18765537.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] PLoS Biol. 2008 Sep 16;6(9):e227 [18798693.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):643-7 [18931657.001]
  • [Cites] Genes Dev. 2008 Dec 1;22(23):3282-91 [19056883.001]
  • [Cites] Cell Metab. 2009 Jan 7;9(1):77-87 [19117548.001]
  • [Cites] Dev Biol. 2009 Feb 15;326(2):378-91 [19041640.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1856-9 [18815287.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Mar;10(3):165-77 [19234476.001]
  • [Cites] Genes Cells. 2009 Mar;14(3):425-34 [19210544.001]
  • [Cites] Am J Hum Genet. 2000 Aug;67(2):295-301 [10856194.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1786-90 [11280723.001]
  • [Cites] Trends Mol Med. 2001 Jan;7(1):18-22 [11427983.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1505-13 [11927535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7142-7 [11997476.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):819-25 [12048269.001]
  • [Cites] Dev Cell. 2002 Sep;3(3):411-23 [12361603.001]
  • [Cites] Development. 2002 Oct;129(20):4797-806 [12361971.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):713-22 [12566318.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Cancer Sci. 2004 Apr;95(4):328-33 [15072591.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2734-45 [10082539.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1037-49 [10215630.001]
  • [Cites] Cell. 1999 Sep 17;98(6):769-78 [10499794.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):14-21 [15632376.001]
  • [Cites] Development. 2005 May;132(9):2179-89 [15829524.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4739-46 [15930292.001]
  • (PMID = 20364082.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD059762; United States / NHLBI NIH HHS / HL / R21 HL082643-01A1; United States / NIDDK NIH HHS / DK / P01-PJ1 DK059820; United States / NICHD NIH HHS / HD / R01 HD059762-05; United States / NICHD NIH HHS / HD / R01HD17379; United States / NICHD NIH HHS / HD / R01 HD059762-01; United States / NIDDK NIH HHS / DK / P01 DK059820; United States / NIDDK NIH HHS / DK / R01 DK045641; United States / NHLBI NIH HHS / HL / R21 HL082643; United States / NHLBI NIH HHS / HL / R21 HL082643-02; United States / NHLBI NIH HHS / HL / R01 HL076448; United States / NICHD NIH HHS / HD / R01 HD059762-04; United States / NICHD NIH HHS / HD / R01 HD017379; United States / NIDDK NIH HHS / DK / R01 DK45641; United States / NICHD NIH HHS / HD / R01 HD059762-02; United States / NICHD NIH HHS / HD / R01 HD059762-02S1; United States / NICHD NIH HHS / HD / R01 HD059762-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / COUP Transcription Factor II; 0 / Neuropilin-2; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor C
  • [Other-IDs] NLM/ PMC2860940
  •  go-up   go-down


77. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


78. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (&gt; or =5-year) follow-up. Am J Surg Pathol; 2005 Jun;29(6):707-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histology of the ovarian primary, extraovarian implants, and recurrent tumor(s) were characterized using World Health Organization criteria and correlated with FIGO stage and clinical follow-up.
  • After censoring nontumor deaths, overall survival and disease-free survival for the 276 patients was 95% (98% FIGO stage I; 91% FIGO II-IV) and 78% (87% FIGO stage I; 65% FIGO stage II-IV), respectively.
  • Unresectable disease (P < 0.001) and invasive implants (P < 0.001) were associated with decreased survival.
  • Stromal microinvasion in the primary tumor was also correlated with adverse outcome, independent of stage of disease, micropapillary architecture, and implant type (P = 0.03).
  • Transformation to low-grade serous carcinoma occurred in 6.8% of patients at intervals of 7 to 288 months (58% > or = 60 months) and was strongly associated with increased tempo of disease and decreased survival (P < 0.001).
  • The majority of S-LMP are clinically benign, but recurrences are not uncommon, and persistent disease as well as deaths occur.
  • Progression to low-grade serous carcinoma is highly predictive of more aggressive disease.
  • Other features associated with recurrent and/or progressive disease include FIGO stage, invasive implants, microinvasion in the primary tumor, and micropapillary architecture.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Child. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897738.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. de Leon MB, Kirsch NL, Maio RF, Tan-Schriner CU, Millis SR, Frederiksen S, Tanner CL, Breer ML: Baseline predictors of fatigue 1 year after mild head injury. Arch Phys Med Rehabil; 2009 Jun;90(6):956-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: Level II community hospital ED.
  • RESULTS: Significant predictors of fatigue severity at 12 months were baseline fatigue, having seen a counselor for a mental health issue, medical disability, marital status, and in some stage of litigation.
  • [MeSH-minor] Adult. Cohort Studies. Female. Hospitals, Community. Humans. Male. Socioeconomic Factors. Trauma Severity Indices

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Head Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480871.001).
  • [ISSN] 1532-821X
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 5-T32-HD007422-17; United States / PHS HHS / / R49/CCR523223-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


80. Makhsous M, Lin F, Knaus E, Zeigler M, Rowles DM, Gittler M, Bankard J, Chen D: Promote pressure ulcer healing in individuals with spinal cord injury using an individualized cyclic pressure-relief protocol. Adv Skin Wound Care; 2009 Nov;22(11):514-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Forty-four subjects, aged 18-79 years, with a Stage II or Stage III PrU, were randomly assigned to the control (n = 22) or treatment (n = 22) groups.

  • MedlinePlus Health Information. consumer health - Pressure Sores.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1987 Nov;107(5):641-8 [3310792.001]
  • [Cites] Geriatr Nurs. 1989 Jul-Aug;10(4):190-2 [2777121.001]
  • [Cites] J Rehabil Res Dev. 1990 Spring;27(2):141-50 [2366198.001]
  • [Cites] JAMA. 1990 Dec 12;264(22):2905-9 [2232085.001]
  • [Cites] West J Med. 1991 May;154(5):539-44 [1830985.001]
  • [Cites] J Rehabil Res Dev. 1992 Fall;29(4):21-31 [1432724.001]
  • [Cites] JAMA. 1993 Jan 27;269(4):494-7 [8338511.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Sep;74(9):947-53 [8379841.001]
  • [Cites] Arch Phys Med Rehabil. 1994 May;75(5):535-9 [8185445.001]
  • [Cites] Paraplegia. 1995 Mar;33(3):141-7 [7784116.001]
  • [Cites] Ostomy Wound Manage. 1997 Jan-Feb;43(1):28-32, 34-5, 38; quiz 39-40 [9087064.001]
  • [Cites] Ann Intern Med. 1981 May;94(5):661-6 [7235399.001]
  • [Cites] Ostomy Wound Manage. 2004 Oct;50(10):40-2, 44-52; discussion 53 [15509881.001]
  • [Cites] Am J Health Syst Pharm. 2004 Sep 15;61(18):1895-905; quiz 1906-7 [15487879.001]
  • [Cites] Am J Surg. 2004 Jul;188(1A Suppl):9-17 [15223496.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001735 [10796662.001]
  • [Cites] Spinal Cord. 2003 Dec;41(12):692-5 [14639449.001]
  • [Cites] Nurs Manag (Harrow). 2003 Oct;Suppl:6-10, 12-4; quiz 14-5 [14694861.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Apr;82(4):529-33 [11295017.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Dec;56(12):M795-9 [11723157.001]
  • [Cites] Wound Repair Regen. 2001 Sep-Oct;9(5):347-52 [11896977.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2002;36(5):279-83 [12477086.001]
  • [Cites] Surg Technol Int. 2003;11:23-31 [12931279.001]
  • [Cites] Ann Intern Med. 2003 Oct 21;139(8):635-41 [14568851.001]
  • [Cites] J Spinal Cord Med. 2007;30(5):497-507 [18092567.001]
  • [Cites] Arch Phys Med Rehabil. 2007 Jul;88(7):862-70 [17601466.001]
  • [Cites] Arch Phys Med Rehabil. 2006 Oct;87(10):1396-402 [17023252.001]
  • [Cites] Adv Skin Wound Care. 2006 Sep;19(7):398-405; quiz 405-7 [16943709.001]
  • [Cites] JAMA. 2006 Aug 23;296(8):974-84 [16926357.001]
  • [Cites] Plast Reconstr Surg. 1998 Sep;102(3):765-72 [9727442.001]
  • [Cites] Adv Wound Care. 1998 Sep;11(5):237-46 [10326341.001]
  • [Cites] Arch Phys Med Rehabil. 1961 Jan;42:19-29 [13753341.001]
  • (PMID = 20026933.001).
  • [ISSN] 1538-8654
  • [Journal-full-title] Advances in skin & wound care
  • [ISO-abbreviation] Adv Skin Wound Care
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD046844-01A1S1; United States / NICHD NIH HHS / HD / R21 HD046844; United States / NICHD NIH HHS / HD / HD047959-01; United States / NICHD NIH HHS / HD / R21 HD046844-01A1; United States / NICHD NIH HHS / HD / HD046844-02; United States / NICHD NIH HHS / HD / R21 HD046844-01A1S1; United States / NICHD NIH HHS / HD / R21 HD046844-02; United States / NICHD NIH HHS / HD / R41 HD047959; United States / NICHD NIH HHS / HD / R41 HD047959-01; United States / NICHD NIH HHS / HD / HD046844-01A1
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167781; NLM/ PMC2860306
  •  go-up   go-down


81. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


82. Handa VL, Nygaard I, Kenton K, Cundiff GW, Ghetti C, Ye W, Richter HE, Pelvic Floor Disorders Network: Pelvic organ support among primiparous women in the first year after childbirth. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Dec;20(12):1407-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of participants, 31.2% had stage II support.
  • [MeSH-minor] Adult. Anal Canal / injuries. Female. Humans. Parity. Pregnancy. Young Adult

  • MedlinePlus Health Information. consumer health - Childbirth.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2000 Aug;183(2):277-85 [10942459.001]
  • [Cites] Am J Obstet Gynecol. 2001 Jul;185(1):11-9 [11483897.001]
  • [Cites] J Urol. 2002 Mar;167(3):1353-5 [11832730.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jun;186(6):1160-6 [12066091.001]
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 1):981-6 [12423864.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):27-32 [14749630.001]
  • [Cites] Obstet Gynecol. 2004 Sep;104(3):489-97 [15339758.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):299-305 [9988790.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Jan-Feb;16(1):69-72; discussion 72 [15647966.001]
  • [Cites] Obstet Gynecol. 2006 Oct;108(4):863-72 [17012447.001]
  • [Cites] Obstet Gynecol. 2006 Dec;108(6):1394-401 [17138772.001]
  • [Cites] Chin Med J (Engl). 2008 Feb 5;121(3):213-5 [18298911.001]
  • [Cites] BJOG. 2008 Jul;115(8):979-84 [18503571.001]
  • (PMID = 19777148.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U10 HD041261; United States / NICHD NIH HHS / HD / U01 HD041249; United States / NICHD NIH HHS / HD / U10 HD41267; United States / NICHD NIH HHS / HD / U10 HD41269; United States / NICHD NIH HHS / HD / U10 HD41261; United States / NICHD NIH HHS / HD / U10 HD41248; United States / NICHD NIH HHS / HD / U10 HD41250; United States / NICHD NIH HHS / HD / U10 HD41268; United States / NICHD NIH HHS / HD / U10 HD041263; United States / NICHD NIH HHS / HD / U10 HD041267; United States / NICHD NIH HHS / HD / U01 HD041249-09; United States / NICHD NIH HHS / HD / U10 HD41263; United States / NICHD NIH HHS / HD / U01 HD41249; United States / NICHD NIH HHS / HD / U10 HD041248; United States / NICHD NIH HHS / HD / UG1 HD041267; United States / NICHD NIH HHS / HD / U10 HD041269; United States / NICHD NIH HHS / HD / U10 HD041268; United States / NICHD NIH HHS / HD / U10 HD041250
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS220446; NLM/ PMC4064938
  • [Investigator] Richter HE; Burgio K; Goode P; Varner RE; Shore G; Tessler F; Lockhart M; Willis V; Fine PM; Appell RA; Thompson PK; Lotze PM; Frierson N; Nygaard I; Brandt D; Haury D; Kreder K; Bradley CS; Rao S; Cundiff G; Handa V; Sauter ME; Wright J; Brubaker L; FitzGerald MP; Kenton K; Koch D; Ball C; Brown MB; Wei JT; Marchant B; DeLancey JO; Janz NK; Smith DG; Wren PA; Ye W; Imus J; Casher YW; Visco AG; Connolly A; Lavelle J; Loomis MJ; Murphy AK; Wells EC; Whitehead W; Fielding J; Zyczynski H; Borello-France D; Hakim C; Wald A; Gruss JA; Leng W; Moalli PA; Park R; Weber AM
  •  go-up   go-down


83. Yang JJ, Park SK, Cho LY, Han W, Park B, Kim H, Lee KS, Hahn SK, Cho SI, Ahn SH, Noh DY, Korean Breast Cancer Society: Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database. Clin Ther; 2010 Jun;32(6):1122-38
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Women with stage I, II, or III breast cancer (diagnosed between 1981 and 2005), for whom information about tamoxifen use (20 mg/d for 5 years) and estrogen-receptor and/or progesterone-receptor status was available, were included.
  • Using a decision analytic model based on standard clinical flow, incremental cost-effectiveness ratios (ICERs) for overall survival were calculated with stratification by disease stage and hormone-receptor status.
  • Among those with stage I or II breast cancer, ICERs for estrogen-receptor positive (ER+)/progesterone-receptor positive (PR+) tamoxifen users ranged from $739 to $1939.
  • In contrast to those with stage I or II disease, tamoxifen use among patients with stage III disease was cost-effective regardless of hormone-receptor status.
  • CONCLUSIONS: In this analysis, postoperative adjuvant tamoxifen use was cost-effective for stage I or II ER+ and/or PR+ breast cancer, but not for ER-/PR- disease.
  • Tamoxifen therapy appeared to be cost-effective for patients with stage III breast cancer regardless of hormone-receptor status.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cohort Studies. Cost-Benefit Analysis. Female. Humans. Korea. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20637966.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Ahn SH; Bae JW; Bae YT; Baek JW; Bong JG; Cha KH; Chang ES; Chang IT; Chang SS; Cho JW; Cho SH; Cho YU; Choi JW; Choi KJ; Choi MS; Choi SI; Choi SY; Goo GS; Han SH; Han W; Hong SJ; Hwang JY; Hyun TI; Im MG; Jegal YJ; Joh YG; Jun SY; Jung BW; Jung J; Jung JH; Jung KH; Jung PJ; Jung SH; Jung SS; Jung YH; Jung YS; Kang DH; Kang HJ; Kang YI; Kang YJ; Keum JH; Kim DY; Kim HJ; Kim JG; Kim JH; Kim JS; Kim JS; Kim KC; Kim SC; Kim SH; Kim SI; Kim SJ; Kim SW; Kim SW; Kim SY; Kim SY; Kim YS; Ko BK; Ko SS; Koh SH; Koo BH; Koo JY; Kwak BS; Lee CH; Lee CH; Lee DH; Lee DS; Lee ES; Lee GS; Lee HD; Lee HS; Lee JC; Lee JH; Lee JK; Lee JS; Lee JY; Lee KM; Lee KP; Lee KS; Lee KY; Lee MH; Lee RA; Lee SC; Lee SJ; Lee SK; Lee W; Lee YH; Leu JW; Lim CH; Lim CW; Moon BI; Nam SJ; Nam YS; Noh DY; Noh WC; Oh SJ; Oh SS; Pae WK; Paik IW; Paik NS; Park BG; Park BW; Park CH; Park HB; Park HY; Park JH; Park KH; Park SJ; Park ST; Park SW; Park WC; Park YK; Park YK; Seo HS; Seo KH; Seo YJ; Sin YS; Son BH; Son GS; Song BJ; Song KH; Song YJ; Suh YJ; Won JM; Woo DH; Yang DH; Yang JH; Yoo KY; Yoo SY; Yoon HS; Yoon JH; Yoon SO
  •  go-up   go-down


84. Lausevic M, Nesic V, Stojanovic M, Stefanovic V: Health-related quality of life in patients on peritoneal dialysis in Serbia: comparison with hemodialysis. Artif Organs; 2007 Dec;31(12):901-10
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who reach end-stage renal disease are older and have a considerable extent of comorbidity.
  • The objectives of this study were (i) to evaluate HRQoL in patients at the initiation of continuous ambulatory peritoneal dialysis (CAPD) treatment (incident cohort) and in patients on long-term CAPD therapy (prevalent cohort), and (ii) to compare influence of comorbidity on HRQoL in CAPD and hemodialysis (HD) patients.
  • In a cross-sectional study we enrolled 99 CAPD and 192 HD patients.
  • CAPD patients with the highest disease severity (Index of Disease Severity [IDS]-3) and physical impairment (Index of Physical Impairment [IPI]-2) scored significantly higher parameters of HRQoL than HD patients.
  • Comorbidity had negative influence on HRQoL, but statistically significant correlation has been found in HD patients only.
  • In conclusion, comorbid conditions had negative correlation with parameters of HRQoL in both CAPD and HD patients.
  • Assessment of HRQoL and comorbidity might be useful in clinical practice in the follow-up of patients treated with both CAPD and HD.
  • [MeSH-minor] Adult. Aged. Comorbidity. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924989.001).
  • [ISSN] 1525-1594
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S: Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs; 2006;9(4):226-33
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 11 diabetic patients (DM) who were not receiving hemodialysis (HD), there were no amputees regardless of their Fontaine classification.
  • Of 19 patients in the HD(+)DM(-) category, there were no amputations in Fontaine stage I, II, and III patients, whereas three limbs and one toe were amputated in Fontaine stage IV patients.
  • Of 13 patients in the HD(-)DM(+) category, none of the Fontaine stage I, II, or III patients underwent amputation, but six Fontaine stage IV patients underwent amputation.
  • Of 49 patients in the HD(+)DM(+) category, 38 (78%) were classified as Fontaine stage IV, 71% (27/38) of whom had a toe or a limb amputated.
  • Therapeutic angiogenesis is effective for critically ischemic limbs resulting from hemodialysis and diabetes until Fontaine stage III, but is of limited effectiveness for stage IV cases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diabetic Angiopathies / surgery. Diabetic Nephropathies / therapy. Female. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Plethysmography. Renal Dialysis. Thermography. Vascular Endothelial Growth Factor A / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171401.001).
  • [ISSN] 1434-7229
  • [Journal-full-title] Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs
  • [ISO-abbreviation] J Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


86. Peluffo MC, Barrett SL, Stouffer RL, Hennebold JD, Zelinski MB: Cumulus-oocyte complexes from small antral follicles during the early follicular phase of menstrual cycles in rhesus monkeys yield oocytes that reinitiate meiosis and fertilize in vitro. Biol Reprod; 2010 Oct;83(4):525-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stage at which follicle-enclosed cumulus-oocyte complexes achieve developmental competence in primates is unknown.
  • Ovaries were removed from adult rhesus monkeys (n = 12) during the early follicular phase (Days 3-4) of spontaneous cycles.
  • Small antral follicles were divided into five groups according to their diameter; group I: <0.5 mm; group II: 0.5-0.99 mm; group III: 1.0-1.49 mm; group IV: 1.5-1.99 mm; and group V: 2.0-2.5 mm.
  • Moreover, the inseminated oocytes can reach the morula stage but arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 1985 Mar;32(2):413-7 [3986271.001]
  • [Cites] Hum Reprod. 1987 Aug;2(6):495-7 [3667906.001]
  • [Cites] Biol Reprod. 1988 Oct;39(3):546-52 [3196788.001]
  • [Cites] Biol Reprod. 1989 Aug;41(2):335-46 [2508776.001]
  • [Cites] Reprod Nutr Dev. 1989;29(5):523-31 [2513833.001]
  • [Cites] Mol Reprod Dev. 1990 Apr;25(4):374-83 [1691651.001]
  • [Cites] Biol Reprod. 1990 Apr;42(4):703-11 [2189504.001]
  • [Cites] Mol Reprod Dev. 1990 Jan;25(1):61-6 [2393585.001]
  • [Cites] Mol Reprod Dev. 1990 Nov;27(3):261-80 [2078341.001]
  • [Cites] Biol Reprod. 1991 Jul;45(1):89-93 [1878439.001]
  • [Cites] Biol Reprod. 1993 Feb;48(2):349-56 [8439624.001]
  • [Cites] Mol Reprod Dev. 1994 Apr;37(4):467-72 [8011332.001]
  • [Cites] Fertil Steril. 1994 Aug;62(2):353-62 [8034085.001]
  • [Cites] Biol Reprod. 1994 Nov;51(5):879-87 [7849190.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1624, 1626 [10577135.001]
  • [Cites] Fertil Steril. 1999 Nov;72(5):845-51 [10560988.001]
  • [Cites] Hum Reprod. 2000 Jan;15(1):165-70 [10611207.001]
  • [Cites] Cancer Treat Rev. 1999 Dec;25(6):323-31 [10644499.001]
  • [Cites] Hum Reprod. 2000 Nov;15(11):2411-4 [11056143.001]
  • [Cites] Biol Reprod. 2001 Jul;65(1):253-9 [11420247.001]
  • [Cites] Reproduction. 2001 May;121(5):647-53 [11427152.001]
  • [Cites] Reproduction. 2001 Oct;122(4):587-92 [11570966.001]
  • [Cites] Fertil Steril. 2001 Nov;76(5):936-42 [11704114.001]
  • [Cites] Hum Reprod. 2002 Aug;17(8):2079-84 [12151440.001]
  • [Cites] Hum Reprod. 2002 Nov;17(11):2825-31 [12407033.001]
  • [Cites] Theriogenology. 2003 Feb;59(3-4):699-707 [12517374.001]
  • [Cites] Biol Reprod. 2003 Mar;68(3):812-21 [12604630.001]
  • [Cites] Hum Reprod. 2003 Apr;18(4):826-33 [12660279.001]
  • [Cites] Biol Reprod. 1994 Nov;51(5):904-12 [7849192.001]
  • [Cites] Hum Reprod. 1995 Apr;10(4):887-95 [7650138.001]
  • [Cites] Endocr Rev. 1996 Apr;17(2):121-55 [8706629.001]
  • [Cites] Mol Reprod Dev. 1996 Jun;44(2):193-9 [9115717.001]
  • [Cites] Reprod Fertil Dev. 1996;8(5):835-41 [8876042.001]
  • [Cites] Hum Reprod. 1996 Aug;11(8):1690-7 [8921118.001]
  • [Cites] Hum Reprod. 1996 Aug;11(8):1698-702 [8921119.001]
  • [Cites] Hum Reprod. 1997 Mar;12(3):403-5 [9130725.001]
  • [Cites] Fertil Steril. 1998 Jun;69(6):996-8 [9627281.001]
  • [Cites] Biol Reprod. 1998 Dec;59(6):1445-53 [9828191.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3132-8 [9853870.001]
  • [Cites] Fertil Steril. 1999 Oct;72(4):639-42 [10521101.001]
  • [Cites] Hum Reprod. 1999 Oct;14(10):2544-55 [10527985.001]
  • [Cites] Mol Reprod Dev. 2005 Jul;71(3):358-67 [15822117.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):318-21 [15983020.001]
  • [Cites] Semin Reprod Med. 2005 Aug;23(3):234-41 [16059829.001]
  • [Cites] Anim Reprod Sci. 2007 Mar;98(1-2):56-71 [17081707.001]
  • [Cites] Tissue Eng. 2006 Oct;12(10):2739-46 [17518643.001]
  • [Cites] Biol Reprod. 2007 Jun;76(6):949-57 [17287496.001]
  • [Cites] Hum Reprod. 2007 Jul;22(7):1925-31 [17437960.001]
  • [Cites] Semin Reprod Med. 2007 Jul;25(4):287-99 [17594609.001]
  • [Cites] Hum Reprod. 2007 Aug;22(8):2232-42 [17562675.001]
  • [Cites] Reprod Sci. 2007 Dec;14(8 Suppl):6-10 [18089604.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):514-22 [18971680.001]
  • [Cites] N Engl J Med. 2009 Feb 26;360(9):902-11 [19246362.001]
  • [Cites] J Reprod Dev. 2009 Feb;55(1):1-10 [19276618.001]
  • [Cites] Am J Primatol. 2009 May;71(5):384-92 [19189308.001]
  • [Cites] Pediatr Blood Cancer. 2009 Aug;53(2):289-95 [19301373.001]
  • [Cites] Biol Reprod. 2009 Sep;81(3):587-94 [19474063.001]
  • [Cites] Hum Reprod. 2009 Oct;24(10):2531-40 [19597190.001]
  • [Cites] Reprod Biomed Online. 2009 Sep;19(3):343-51 [19778479.001]
  • [Cites] Semin Reprod Med. 2009 Nov;27(6):443-9 [19806512.001]
  • [Cites] Semin Reprod Med. 2009 Nov;27(6):450-5 [19806513.001]
  • [Cites] Fertil Steril. 2010 Mar 15;93(5):1550-5 [19423101.001]
  • [Cites] Fertil Steril. 2010 May 1;93(7):2202-9 [19249763.001]
  • [Cites] Hum Reprod. 2003 Aug;18(8):1632-6 [12871873.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5307-14 [14602766.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jun 16;2:31 [15200680.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):486-93 [15044263.001]
  • [Cites] Hum Reprod. 2004 Sep;19(9):2109-17 [15243006.001]
  • [Cites] Lancet. 2004 Oct 16-22;364(9443):1405-10 [15488215.001]
  • [Cites] Lancet. 1965 Nov 6;2(7419):926-9 [4165802.001]
  • [Cites] J Exp Zool. 1974 Oct;190(1):123-7 [4436619.001]
  • [Cites] J Reprod Fertil. 1975 Oct;45(1):83-90 [1195259.001]
  • [Cites] J Reprod Fertil. 1977 Sep;51(1):1-15 [335057.001]
  • [Cites] Biol Reprod. 1982 Nov;27(4):989-97 [7171676.001]
  • [Cites] J Clin Endocrinol Metab. 1983 May;56(5):1022-31 [6403567.001]
  • [Cites] Biol Reprod. 1983 May;28(4):983-99 [6683110.001]
  • [Cites] Recent Prog Horm Res. 1983;39:1-73 [6415767.001]
  • [Cites] Dev Biol. 1984 Apr;102(2):493-7 [6706011.001]
  • (PMID = 20519694.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / RL1 HD058294; United States / NICHD NIH HHS / HD / U54 HD55744; United States / NICHD NIH HHS / HD / T32-HD007068-3; United States / NCRR NIH HHS / RR / P51 RR000163; United States / NICHD NIH HHS / HD / R01-HD058294; United States / NICHD NIH HHS / HD / RL1HD058295; United States / NCRR NIH HHS / RR / RR00163; United States / NIBIB NIH HHS / EB / PL1 EB008542; United States / NCRR NIH HHS / RR / K01 RR000163; United States / NIDCR NIH HHS / DE / UL1 DE019587; United States / NCRR NIH HHS / RR / UL1 RR024926; United States / NICHD NIH HHS / HD / RL1 HD058295; United States / NICHD NIH HHS / HD / U54 HD18185; United States / NICHD NIH HHS / HD / U54 HD055744; United States / NIDCR NIH HHS / DE / UL1DE019587; United States / NICHD NIH HHS / HD / T32 HD007068; United States / NCRR NIH HHS / RR / 1 UL1 RR024926; United States / NICHD NIH HHS / HD / U54 HD018185; United States / NIBIB NIH HHS / EB / PL1-EB008542
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2957158
  •  go-up   go-down






Advertisement